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ABSTRACT  
Diabetes is a prevalent metabolic disorder that affects various body functions and systems. Effects 
of diabetes on cognitive function have been reported in animal models of diabetes, particularly 
learning and memory impairments and changes in hippocampal synaptic plasticity such as long-
term potentiation (LTP), which depends primarily on NMDA and AMPA subtypes of glutamate 
receptors. The Receptor for Advanced Glycation End-products (RAGE) has been particularly 
implicated in vascular and peripheral nervous system complications of diabetes. These 
observations led us to hypothesize that RAGE signaling in models of diabetes can alter the function 
of NMDA and AMPA subtypes of glutamate receptors, leading to dysfunction in synaptic 
transmission and subsequent impairment in learning and memory.   
Our findings showed that although recognition memory was unaffected in streptozotocin (STZ)-
induced diabetes in both genotypes, hippocampal-dependent spatial memory was impaired in STZ-
induced diabetic mice in wild-type (WT) but not in the RAGE knockout (RAGE-KO) group. This 
impairment in spatial memory was consistent with deficits in synaptic plasticity, i.e. LTP and 
paired pulse facilitation (PPF), and reduction in the expression and phosphorylation of the GluA1 
subunit of the AMPA receptor in WT STZ-induced diabetic mice. These changes were associated 
with the activation of the mitogen activated protein kinase (MAPK) pathway, leading to increased 
total p38, phospho-p38, and nuclear factor-kappa beta (NF-κB) and decreased phospho c-Jun N-
terminal kinase (pJNK) and its kinase, mitogen activated protein kinase kinase 7 (pMEK7). In WT 
hippocampal cultures, high glucose caused a reduction of AMPA-evoked currents, as well as a 
reduction in cell excitability, and an increase in cytosolic ROS.  
This is the first study, to the best of our knowledge, that shows the contribution of RAGE signaling 
in abnormal hippocampal synaptic transmission and cognitive function in diabetes, which could 
help identify potential targets for therapeutic interventions.  
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CHAPTER 1 
GENERAL INTRODUCTION 
 
1.1 Diabetes  
Diabetes is a complex metabolic disorder characterized by elevated blood glucose level 
(hyperglycemia) due to deficits in insulin secretion or resistance to insulin action, or both 
(Kharroubi and Darwish 2015). The vast majority of diabetic cases are classified into one of two 
broad categories: type 1 diabetes, which is caused by the autoimmune destruction of insulin-
secreting pancreatic beta cells, or type 2 diabetes, which is caused by a combination of resistance 
to insulin action and an inadequate insulin secretion (Kharroubi and Darwish 2015). In addition, a 
transient form of diabetes developed during the course of pregnancy is classified as gestational 
diabetes (Alfadhli 2015). Hyperglycemia is the hallmark characteristic of all types of diabetes and 
it has the potential to cause long-lasting complications due to its chronic nature (Papatheodorou et 
al., 2015). These complications are divided into microvascular and macrovascular, with the former 
having much higher prevalence than the latter (Deshpande et al., 2008; Papatheodorou et al., 
2015). Microvascular complications include damage to the kidneys (nephropathy) leading to renal 
failure, to the eyes (retinopathy) with potential loss of vision, and to the nerves (neuropathy) 
leading to sensory loss, and damage to the limbs as well as to the gastrointestinal and genitourinary 
systems (American Diabetes Association 2010). Macrovascular complications, on the other hand, 
can lead to atherosclerosis, cardiovascular, peripheral arterial, and cerebrovascular diseases and 
stroke (American Diabetes Association 2010). These complications represent the leading causes 
of diabetes-related morbidity and mortality worldwide (Cusick et al., 2005). In addition to micro- 
and macrovascular complications, hyperglycemia can also affect cells directly, in particular 
neurons, independently of the vasculature, in a phenomenon known as glucose neurotoxicity 
(Tomlinson and Gardiner, 2008), which is linked to oxidative stress and activation of a number of 
signaling pathways.  
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1.2 Diabetes and the central nervous system (CNS)  
It has been traditionally accepted that the CNS was spared from diabetic complications since it 
was considered an insulin-independent organ with constant glucose levels (Ahmadpour 2012; 
Blázquez et al. 2014). However, in recent decades, studies have provided strong pieces of evidence 
that not only show important functions of insulin in the brain (Blázquez et al. 2014; Gray et al., 
2014), but also confirm changes in brain glucose concentrations following diabetic/hyperglycemic 
states (Jacob et al., 2002; Elizabeth et al., 2012). The effects of diabetes on the CNS, known as 
diabetic encephalopathy (Sima, 2010), is linked to structural and functional changes (Stiles 
and Seaquist 2010; Seaquist 2015; Moheet et al., 2015). Alterations in neurotransmission, 
electrophysiological abnormalities, and neurobehavioural changes are widely reported in the 
diabetic brain (Trudeau et al., 2004; Li and Sima 2004; Malone 2016). In particular, demyelination 
and delayed conduction velocity (Manschot et al., 2003; Huang et al., 2012), degenerative changes 
and neuronal loss (Sadeghi et al., 2016), cerebral atrophy (Šerbedžija et al., 2012), impaired 
neurogenesis (Stranahan et al., 2008; Dorsemans et al., 2017), increased gliosis (Wanrooy et al., 
2018), enlarged lateral ventricles (Mazaika et al., 2018), white matter hyperintensities (Weinger et 
al., 2008), increased blood-brain barrier (BBB) permeability (Hawkins et al., 2007), impaired 
synaptic plasticity (Gispen and Biessels 2000), changes in neurotransmitter synthesis and release 
(Trudeau et al., 2004), cerebral ischemia (Shukla et al., 2017), and increased risks of cognitive 
dysfunction (Kodl and Seaquist 2008) such as dementia (Gudala et al., 2013) and depression 
(Bădescu et al., 2016a) have been observed in clinical and experimental diabetes (Li and Sima 
2004; Biessels and Reijmer 2014).  
 
1.2.1 Diabetes and cognitive function 
Diabetes is accompanied by an erosion of cognitive function, as shown by longitudinal and cross-
sectional studies in diabetic patients (Trudeau et al. 2004). Perhaps, the most recognizable negative 
impact of diabetes in cognitive function is its connection to dementia. Type 2 diabetes has long 
been considered a risk factor for Alzheimer's disease (AD), vascular dementia, and other forms of 
dementia (Lee et al., 2018). Reports concentrating on the prevalence of diabetes and AD, and 
hyperglycemia as a risk factor for AD, strongly support a link between these two diseases 
(González-Reyes et al., 2016; Kim et al., 2016; Pruzin et al., 2018). Particularly, hyperglycemia 
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increases amyloid β accumulation on brain lesions, as well as increase oxidative stress, markers of 
neuroinflammation, mitochondrial dysfunction, and neurodegeneration (Macauley et al., 2015; 
Rom et al., 2018; Silzer et al., 2018).  
Cognitive decline has been widely reported in type 2 diabetic patients. Among the most commonly 
cognitive functions affected are psychomotor speed, executive function, verbal memory, 
processing speed, complex motor functioning, working memory, immediate and delayed recall, 
verbal fluency, visual retention, and attention (Gregg et al., 2000; Grodstein et al., 2001; 
Fontbonne et al., 2001; Munshi et al., 2006; Kanaya et al., 2004; Messier, 2005; Kodl and Seaquist, 
2008; Moheet et al., 2015). Furthermore, the incidence of cognitive decline in type 2 diabetic 
patients correlates with the duration of disease (Kodl and Seaquist, 2008). Although diabetes might 
also increase the risk of young-onset dementia (that is, before the age of 65), the vast majority of 
individuals with diabetes who develop dementia are over the age of 65 (Biessels and Despa, 2018).  
Similarly, type 1 diabetic patients show negative impact on cognitive functions such as information 
processing speed, psychomotor efficiency, attention, memory, learning, problem solving, motor 
speed, general intelligence, visuoconstruction, visual perception, somatosensory examination, 
motor strength, mental flexibility and executive function (Kodl and Seaquist, 2008; Brands et al., 
2005; Wessels et al., 2007; Perantie 2008; Northam 2009; Ohmann 2010; Moheet et al., 2015). 
Although hallmark complications of diabetes affecting peripheral tissues, such as retinopathy and 
nephropathy, usually develop later in the course of the disease, the onset of cognitive dysfunction 
has been found to develop early in patients with type 1 diabetes (Kodl and Seaquist, 2008). 
Cognitive functions, including general intelligence, vocabulary, learning, and speed of information 
processing, for example, have been affected as early as 2 years after diagnosis in children with 
type 1 diabetes (Northam et al., 1998).  
Cognitive dysfunction, especially learning and memory impairments, have also been widely 
reported in animal models of diabetes (Kodl and Seaquist 2008; Wrighten et al., 2009; Rostami et 
al., 2013, Moheet et al., 2015; Saedi et al., 2016).  
Table 1.1 provides a summary of cognitive domains that negatively affected by diabetes in type 1 
and type 2 diabetic patients.   
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Table 1.1 Summary of cognitive domains that are negatively affected by diabetes in type 1 and 
type 2 diabetic patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cognitive Domain  Type of Diabetes  Citation  
Information processing speed Type 1 and type 2 Brands et al., 2006; Kodl and Seaquist, 2008 
Psychomotor speed  Type 1 and type 2 Ryan et al., 2003; Gregg et al., 2000 
Attention Type 1 and type 2 Wessels et al., 2007; Fontbonne et al., 2001 
Learning and memory Type 1 and type 2 Weinger et al., 2008; Zilliox et al., 2016  
Executive function Type 1 and type 2 Munshi et al., 2006; Weinger et al., 2008 
Problem solving Type 1  Kodl and Seaquist, 2008 
Motor speed and strength Type 1 Ryan et al., 2003 
Vocabulary Type 1 Weinger et al., 2008 
General intelligence Type 1 Northam et al., 1998 
Visuoconstruction Type 1 Wessels et al., 2007 
Mental flexibility Type 1  Kodl and Seaquist, 2008 
Verbal memory Type 2 Messier, 2005 
Delayed and immediate recall  Type 2 Grodstein et al., 2001 
Complex motor function Type 2 Kumar et al., 2009  
Verbal fluency Type 2 Kanaya et al., 2006 
Depression Type 2 Bruce et al., 2003; Holt et al., 2014  
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1.2.2 Pathogenesis of CNS complications of diabetes  
Among the several factors involved in the pathogenesis of CNS complications in diabetes, 
hyperglycemia-induced oxidative stress and insulin/C-peptide deficiency are considered critically 
important (Li and Sima 2004; Muriach et al., 2014). Hyperglycemia-induced oxidative stress is 
one of the well-investigated theories regarding diabetes-induced CNS complications (Li and Sima 
2004; Muriach et al., 2014). It is well known that hyperglycemia induces oxidative stress through 
the polyol pathway, enhanced production of mitochondrial reactive oxygen species (ROS), 
increased nonenzymatic glycation of proteins, glucose autoxidation, enhanced lipid peroxidation 
by-products, and eventually imbalances in the generation of ROS and their scavengers (Mercuri et 
al., 2000; Lipinski 2001; Opara 2002; Li and Sima 2004).  
High lipid content and oxygen consumption rate and relative paucity of antioxidant enzymes make 
the brain especially vulnerable to such oxidative stress (Muriach et al., 2014; Barcia et al., 2015). 
One of the main consequences of oxidative stress is the activation of stress-sensitive signaling 
pathways such as c-Jun N-terminal kinase/stress-activated protein kinases (JNK/SAPK), p38 
mitogen-activated protein kinase (MAPK), advanced glycosylation end-products (AGEs)/receptor 
for AGEs (RAGE), and subsequent activation of nuclear factor-κB (NF-κB) and the production of 
gene products which cause cellular and tissue damage and chronic complications of diabetes 
(Evans et al., 2002).  
In addition to oxidative stress-mediated complications, deficiency in the insulin/C-peptide, a 
peptide cleaved from proinsulin during the insulin biosynthesis, is also proposed as another 
mechanism underlying diabetes-induced CNS complications (Li and Sima 2004; Sima et al., 
2004). Insulin in the brain contributes to numerous distinct roles such as regulating energy 
expenditure, glucose uptake and homeostasis, feeding behaviour, reproduction, cell proliferation 
and differentiation, cognition, and memory, in addition to its neuromodulatory, neurotrophic and 
neuroprotective effects (Blázquez et al. 2014; Gray et al., 2014). Insulin deficiency is shown to 
play an important role in diabetes-induced neuronal loss/apoptosis in the CNS (Li and Sima 2004; 
Sima et al., 2004). Treatment with insulin mediated an anti-apoptotic effect and partially corrected 
diabetes-induced cognitive deficits (Li et al., 2003; Li and Sima 2004; Sima et al., 2004). Similarly, 
treatment with C-peptide was able to prevent neuronal apoptosis in the hippocampus of diabetic 
rats (Li et al., 2002b).         
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The role of diabetes-induced oxidative stress and neuronal loss in CNS complications is most 
extensively studied in the hippocampus (Li et al., 2002a; Yang et al., 2013; Foghi  and Ahmadpour 
2013; Muriach et al., 2014; Sadeghi et al., 2016; Ahmad et al., 2017).  
 
 
1.2.3 Diabetes and the hippocampus  
1.2.3.1. Hippocampus structure and function  
Hippocampus is a part of the limbic system that is located alongside the medial to inferior horn of 
the lateral ventricle in the temporal lobe of the cerebral cortex (Campbell  and MacQueen 2004). 
The hippocampus has a highly distinctive morphology, composed of two regions, the Cornu 
Ammonis (CA) and the dentate gyrus (DG) which principally contain the pyramidal cells and the 
granule cells respectively (Taupin 2007). The CA region itself can be divided into CA1, CA2, 
CA3, and CA4 subregions based on pyramidal neuron morphology (Campbell  and MacQueen 
2004). The hippocampus forms a unidirectional network, with input from the entorhinal cortex 
that makes connections with the DG and CA3 pyramidal neurons through the perforant path. In 
addition to input from entorhinal cortex, CA3 pyramidal neurons also receive input from the DG 
via the mossy fibre pathway and send axons to CA1 pyramidal neurons via the Schaffer collateral 
pathway, as well as to the contralateral hippocampus through the associational/commissural 
pathway. CA1 pyramidal neurons receive inputs from the perforant path as well and send axons to 
the subiculum, which in turn send the main hippocampal output back to the entorhinal cortex and 
form a loop (Kesner 2013) (Figure 1.1).  
 
 
 
 
 
 
 
 
 
 
7 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. The neuronal circuitry in the hippocampus. Layer II neurons in the entorhinal 
cortex (EC) send axons to the dentate gyrus via the lateral perforant pathway (LPP) and the medial 
perforant pathway (MPP). The dentate gyrus then projects to CA3 pyramidal neurons through the 
mossy fibre pathway. CA3 pyramidal neurons send the information to pyramidal neurons in CA1 
via the Schaffer collateral pathway, which in turn send back-projections into deep-layer neurons 
of the EC (Reproduced with permission from Deng et al., 2010).  
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The hippocampus is also a part of the brain that shows a high degree of synaptic plasticity (Taupin 
2007). It is also one of the unique regions of the brain where neurogenesis continues throughout 
adulthood (Bonfanti and Peretto 2011; Anand and Dhikav 2012).  
The hippocampus is involved in several important physiological functions such as learning and 
memory, spatial navigation, emotional behaviours, and regulation of hypothalamic functions 
(Anand  and Dhikav 2012).  Many of these physiological hippocampal functions are mediated, at 
least in part, by the two major subtypes of ionotropic glutamate receptors in the CNS, N-methyl-
D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methylisoxazole propionate (AMPA) 
receptors (Voglis and Tavernarakis 2006). NMDA receptors are tetrameric assemblies of different 
subunits (GluN1, GluN2A-D and GluN3A-B) and act as non-selective cation channels (Hansen et 
al., 2018). To open the cation pore, they require the binding of glutamate and glycine, coupled 
with depolarization of the postsynaptic membrane to relieve the magnesium (Mg2+) blockade from 
the channel’s pore (Voglis and Tavernarakis 2006). AMPA receptors, on the other hand, are 
tetrameric ion channels composed of different subunits (GluA1-GluA4) that conduct sodium (Na+) 
and potassium (K+) ions primarily, although they can be permeable to calcium as well depending 
on their subunit composition (Gouaux, 2004). The effect of glutamate on the hippocampal 
excitatory synapses has a dual effect mediated by both types of ionotropic excitatory receptors, a 
fast component mediated by AMPA receptors and a slow component mediated by NMDA 
receptors (Huganir and Nicoll 2013; Strong et al., 2014). 
In the CA1 region of the hippocampus, it is now well known that the induction of long-term 
potentiation (LTP) is primarily mediated by AMPA and NMDA subtypes of glutamate receptors 
(Lynch, 2004; Citri and Malenka, 2008). LTP is a form of synaptic plasticity that serves as an 
important electrophysiological tool for the study of processes involved in learning and memory 
(Baudry and Lynch 2001; Lynch 2004). AMPA-mediated rapid responses to synaptically released 
glutamate can shift the membrane potential from resting to a depolarized potential and relieve 
Mg2+ blockade of NMDA receptors (Fleming and England, 2010). Once open, NMDA receptors 
allow calcium (Ca+) influx into the postsynaptic neuron, triggering various signaling cascades 
involved in the regulation of the expression, trafficking and function of glutamate receptors, 
especially AMPA receptors, which are critical for the generation of synaptic potentiation (Baudry 
and Lynch 2001; Fleming and England, 2010).  
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The regulation of AMPA receptors is primarily mediated by two mechanisms: 1) phosphorylation 
of the receptor subunits by kinases that become activated following NMDA-mediated Ca+ influx, 
and the subsequent increase in the open probability of the receptor, and 2) changes in the surface 
expression of the receptor at the postsynaptic membrane, such as insertion of new AMPA receptors 
following Ca2+-mediated cascades (Voglis and Tavernarakis 2006) (Figure 1.2). 
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Figure 1.2. Hippocampal synaptic plasticity and glutamate receptors. Glutamate released 
from the presynaptic terminal binds to the glutamate receptors at the postsynaptic terminal, leading 
to the passage of Na+ from AMPA and kainate receptors and subsequent postsynaptic 
depolarization. This shift in the membrane potential triggers the release of Mg2+ from the NMDA 
receptor. Ca+ influx through the NMDA receptor initiates various signaling cascades, such as 
further regulating the expression, trafficking and phosphorylation of AMPA receptors, which is 
critical for the generation of synaptic potentiation (Reproduced with permission from Voglis and 
Tavernarakis 2006).  
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The hippocampus is shown to be very vulnerable to a variety of insults including stress, hypoxia, 
ischemia, aging, and metabolic disturbances such as those taking place in diabetes (Di Paola et al., 
2008; Stranahan et al., 2008; Murray et al., 2014; Bartsch and Wulff 2015; Bartsch et al., 2015; 
Gasparova et al., 2018). Diabetes results in a variety of functional and structural changes in the 
hippocampus, and some of the most common will be discussed below. 
 
1.2.3.2.  Increased neuronal loss and decreased neurogenesis 
Increased neuronal cell loss/apoptosis is widely reported in the hippocampus of spontaneous and 
induced animal models of diabetes (Li et al., 2002a; Sima and Li 2005; Lebed et al., 2008; Rostami 
et al., 2013; Sadeghi et al., 2016). These kinds of neurodegenerative alterations are suggested to 
underlie the volumetric changes observed in the hippocampus in diabetes, such as a reduction of 
grey matter density in diabetic humans, especially in those with poorer glycemic control (Musen 
et al., 2006; Ates et al., 2007; foghi et al., 2013). In addition to increased neuronal loss, an ample 
body of literature shows significant decrease in hippocampal neurogenesis in animal models of 
diabetes (Jackson-Guilford et al., 2000; Saravia et al., 2004; Beauquis et al., 2006; Stranahan et 
al., 2008; Zhang et al., 2008; Ho et al., 2013). Diabetes-induced inflammation is suggested as one 
of the mechanisms involved in reduced hippocampal neurogenesis (Chesnokova et al., 2016). Pro-
inflammatory cytokines are shown to suppress hippocampal neural progenitor cell proliferation 
(Chesnokova et al., 2016). Proinflammatory cytokines can induce the hypothalamic-pituitary-
adrenal (HPA) axis to become hyperactive and cause an elevation in glucocorticoid levels, which 
in turn disrupt hippocampal neurogenesis due to the high density of glucocorticoid receptors 
(GCRs) in the hippocampus (Stranahan et al., 2008; Chesnokova et al., 2016; Odaka et al., 2017). 
High levels of cytokines, on the other hand, can induce apoptosis of newborn neurons and trigger 
oxidative stress that damages the developing neurons (Chesnokova et al., 2016). 
 
1.2.3.3 Astroglial alterations  
Astrocytes, the most abundant cell type in the CNS, play an important role in brain energy 
metabolism and are therefore a major potential target during abnormal glucose homeostasis, such 
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as in diabetes (Prebil et al., 2011; Jha and Morrison 2018). Hyperglycemia is shown to affect 
primary astrocytes in culture by increasing inflammatory cytokine expression, ROS production, 
and cell death, as well as by inhibiting proliferation and migration (Wang et al., 2012; Li et al., 
2018). In addition, high glucose is reported to increase glycolytic metabolism and enhance 
adenosine triphosphate (ATP) and glycogen content in cultured astrocytes, leading to changes in 
energy metabolism (Li et al., 2018). Hyperglycemia also caused deficits in gap junctional 
communication between astrocytes in cultures as well as in brain slices of STZ-treated rats (Gandhi 
et al., 2010). Moreover, increases in glial fibrillary acidic protein (GFAP) and S100 calcium-
binding protein B (S100B) expression have been observed in the hippocampus of rodent models 
of diabetes, indicating increases in astrocyte reactivity in response to diabetes (Saravia et al., 2002; 
Baydas et al., 2003a; Coleman et al., 2004). Remarkably, these effects were attenuated by 
antioxidant treatment, which further supports the central role of oxidative stress in mediating 
diabetes-induced astroglial alterations (Baydas et al., 2003a; Okuyama et al., 2018).  
 
1.2.3.4 Impairment in synaptic plasticity 
Synaptic plasticity – the ability of synapses to change their synaptic strength in response to specific 
patterns of activity – is modulated by morphological and biochemical mechanisms that are thought 
to be the cellular events underling learning and memory (Massaad and Klann 2011). 
Morphological studies show a decreased length of apical dendrites as well as a reduced number of 
apical branch points of CA3 pyramidal neurons in STZ-induced diabetic rats (Magarinos and 
McEwen 2000), which may be linked to electrophysiological dysfunctions in the CA1 region of 
the hippocampus (Trudeau et al., 2004). In fact, deficit in the expression of LTP at hippocampal 
CA3–CA1 synapses is considered by many as one of the main underlying mechanisms of diabetes-
induced cognitive impairments (Biessels et al., 2002; Trudeau et al., 2004; Kumar 2011). 
Impairment in LTP is well documented in animal models of diabetes (Izumi et al., 2003; Trudeau 
et al., 2004 ; Artola et al., 2005; Kumar 2011; Sasaki-Hamada et al., 2012; Grillo et al., 2015).  
Both pre- and postsynaptic components are suggested to contribute to LTP alterations in the 
hippocampus in diabetes (Trudeau et al., 2004). At the presynaptic level, changes in LTP might be 
caused by alterations in neurotransmitter synthesis and release (Trudeau et al., 2004). In this 
regard, measurements of paired pulse facilitation (PPF) – a form of presynaptic plasticity – is 
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considered as a useful electrophysiological tool for detection of changes in presynaptic function, 
such as probability of neurotransmitter release (Jackman and Regehr 2017). Changes in 
neurotransmitter synthesis or release in diabetes are reported in several brain regions including the 
hippocampus (Trudeau et al., 2004). In contrast, at the postsynaptic level, changes in LTP can be 
linked to modifications in expression and function of glutamate receptors.  
 
1.2.3.5 Changes in expression and function of glutamate receptors  
Glutamate receptors, the major excitatory receptors in the central nervous system, play important 
roles in controlling synaptic plasticity during learning and memory processes (Voglis 
and Tavernarakis, 2006). Abnormal regulation of glutamate receptors thus appears to mediate 
diabetes-induced impairment in synaptic plasticity and the development of cognitive deficits 
(Trudeau et al., 2004).  
Findings in the diabetic hippocampus describe changes in AMPA and NMDA receptors expression 
and function, which may help explain the impaired synaptic plasticity found in diabetic models. 
STZ induced-diabetic animals showed changes in electrophysiological properties (Gardoni et al, 
2002; Marshad et al., 2018) as well as in the expression level of different subunits of NMDA 
receptors in the hippocampus (Valastro et al, 2002; Gardoni et al, 2002; Nardin et al, 2016; Wang 
et al., 2019). Similarly, changes in the electrophysiological properties of AMPA receptors as well 
as in the expression and post-translational modifications of AMPA receptor subunits are reported 
in animal models of diabetes (Valastro et al., 2002; Trudeau et al., 2004; Castilho et al., 2012; 
Wang et al., 2019). These changes in glutamate receptors, which will be discussed thoroughly in 
Chapter 4, are linked to impairment in synaptic plasticity and cognitive function in diabetic models 
(Valastro et al., 2002; Trudeau et al., 2004; Sasaki-Hamada et al., 2012; Wang et al., 2019).  
  
1.3 AGEs and their receptor   
In recent years, a large number of studies have focused on the factors contributing to the 
pathogenesis of diabetic complications. Hyperglycemia is still considered the primary cause of 
diabetic complications (Peppa et al., 2003). Its deleterious effects are attributable, at least in part, 
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to the formation of AGEs (Peppa et al., 2003; Singh et al., 2014). AGEs are a complex and 
heterogeneous group of molecules formed from the nonenzymatic reaction of glucose with free 
amino groups of lipids, proteins, and nucleic acids, called the Millard reaction (Ulrich and Cerami 
2001; Cho et al., 2007). This reaction occurs increasingly in the body as we age and is accelerated 
under conditions of elevated glucose availability, i.e. hyperglycemia, (Nass et al., 2007). AGEs 
are also formed through the polyol pathway, which becomes active when intracellular glucose 
concentrations are elevated (Lorenzi 2007). The fructose produced by the polyol pathway can 
become phosphorylated and break down into compounds that are powerful glycosylating agents 
and enter into the formation of AGEs (Lorenzi 2007). In addition to the abovementioned pathways, 
AGEs can also arise from products of autoxidation of glucose, which yields highly reactive 
oxidative compounds (Daroux et al., 2012). AGEs bind to their receptor, RAGE, which is a 
member of the immunoglobulin superfamily of cell surface molecules (Singh et al., 2014) and is 
expressed in a variety of cell types such as immune cells, neurons, astrocytes, skeletal cells, 
endothelial cells, smooth muscle cells, myocardial cells, and alveolar epithelial cells (Nedić et al., 
2013). RAGE is composed of five domains including three extracellular domains (a V-type domain 
with ligand binding properties and two C-type domains), a single transmembrane domain that 
anchors RAGE to the membrane and a short C-terminal cytosolic tail that mediates interaction 
with cytosolic transduction molecules (Stern et al. 2002; Singh et al., 2014).  
Several isoforms of RAGE are reported, including the full-length RAGE (fRAGE), the membrane-
bound RAGE lacking the extracellular ligand binding domain (N-truncated form, ΔN RAGE), the 
dominant-negative RAGE (DN RAGE) lacking the C-terminal cytosolic tail, and the soluble 
RAGE lacking the transmembrane domain but conserving the binding domain. Soluble RAGE, 
which acts as a decoy receptor to sequester circulating ligands (Han et al., 2011), is divided into 
two subcategories, i.e. endogenous secretary RAGE (esRAGE) and cleaved RAGE (cRAGE), with 
the former generated from the splice variants and the latter via the cleavage of full-length RAGE 
by a membrane α-secretase, a disintegrin and metalloproteinase 10 (ADAM 10) and matrix 
metalloproteinase 9 (MMP9) (Han et al., 2011) (Figure 1.3).  
Although initially identified as a receptor for AGEs, RAGE is a multiligand receptor that binds to 
a variety of ligands such as S-100 calcium-binding protein, high-mobility group box 1 protein 
(HMGB1), Amyloid-β (Aβ), macrophage-1 antigen (Mac-1), and phosphatidylserine, to mention 
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a few (Fritz 2011). Most RAGE ligands are involved in acute and chronic inflammatory events, 
and many signaling cascades triggered by RAGE lead to the production and activation of pro‐
inflammatory and inflammatory mediators (Riuzzi et al., 2018). It is not thus surprising that RAGE 
is implicated in a number of pathological conditions such as atherosclerosis, arthritis, stroke, 
neurodegeneration, cancer and diabetes (Riehl et al., 2009; Riuzzi et al., 2018).  
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Figure 1.3. RAGE isoforms.  Different isoforms of RAGE are generated from alternative 
mRNA splicing and/or proteolytic cleavage by ADAM10 and MMP9. Full-length RAGE 
(fRAGE), membrane-bound RAGE (N-truncated form, ΔN RAGE), dominant-negative RAGE 
(DN RAGE), endogenous secretary RAGE (esRAGE), and cleaved RAGE (cRAGE) (Reproduced 
with permission from Han et al., 2011).  
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1.3.1 RAGE and diabetic complications  
RAGE plays an important role in the development of diabetic complications such as nephropathy, 
retinopathy, neuropathy, and macrovascular diseases (Ramasamy et al., 2005; Yamaguchi et al., 
2009; Chen et al., 2012; Kanasaki et al., 2013; Manigrasso et al., 2014).  
In the kidneys, for example, RAGE is expressed in a number of cell types, such as podocytes and 
endothelial cells (Manigrasso et al., 2014). Diabetes-induced AGEs accumulation is more 
prominent in the kidney since it is a major site of AGEs clearance (Manigrasso et al., 2014). In 
addition, STZ-induced hyperglycemia upregulates renal expression of HMGB1 in glomerular and 
tubular epithelial cells in parallel with increased RAGE expression (Kim et al., 2011). The 
appearance of another RAGE ligand, S100, in the podocyte was associated with more severe 
clinical and pathological indices of diabetic nephropathy (Yamaguchi et al., 2009). Engagement 
of RAGE with its ligands leads to the generation of ROS and amplifies inflammation (Sanajou et 
al., 2018). In addition to reducing antioxidant enzymes and cellular glutathione levels, RAGE 
activation results in the upregulation of nicotinamide adenine dinucleotide phosphate oxidase 
(NADPH oxidase), nitric oxide synthase (NOS), and cyclooxygenase (COX), leading to 
exacerbation of inflammatory responses in the kidneys (Kim et al., 2010; Sanajou et al., 2018). 
Such chronic inflammatory states are mediated largely by RAGE-induced NF-κB activation that 
enhances the expression and production of various inflammatory cytokines, chemokines, and 
adhesion molecules in the diabetic kidneys (Kanasaki et al., 2013). RAGE deletion was beneficial 
in delaying the progression of diabetic renal disease (Manigrasso et al., 2014).  
In concert with the abovementioned findings, RAGE and its ligands AGEs, HMGB1, and S100 
showed significant upregulation in the diabetic eye, thereby implicating RAGE as a major player 
in the development of diabetic retinopathy (Manigrasso et al., 2014). Interaction of RAGE with its 
ligands in the diabetic retina induces inflammatory responses through the MAPKs-NF-κB 
pathway, thereby leading to the disruption of the retinal vascular barrier (Mohammad et al., 2013). 
Inhibition of RAGE was able to block the development of certain lesions of diabetic retinopathy 
(Chen et al., 2012).  
RAGE expression is also increased in peripheral neurons in diabetic neuropathy (Juranek et al., 
2013), and lack of its expression prevented cellular changes in autonomic (Chandna et al, 2015a) 
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and sensory (Lam et al., 2018) neurons. RAGE-induced oxidative stress and activation of the 
polyol pathway was associated with dysregulation of PKC and (Na+, K+)-ATPase activity and 
subsequent impairment in nerve function (Wada and Yagihashi 2005). Similarly, diabetes-induced 
endothelial injury in the peripheral nervous tissues was mediated through the AGE-RAGE axis 
and the involvement of MAPKs, Ras homologous (Rho) GTPases, phosphoinositol-3 kinase 
(PI3K), and Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling 
pathways, finally resulting in NF-κB activation and subsequent expression of numerous pro-
inflammatory molecules; in addition, many of these pathways lead to the generation of ROS by 
NADPH oxidase, thereby exacerbating the development of micro- and macrovascular 
complications of diabetes (Wautier et al., 2001; Wada and Yagihashi 2005; Daroux et al., 2012). 
The activation of precise RAGE-mediated signaling pathways thus appears to be dependent on the 
cell type as well as the degree of the cellular stress (Daffu et al, 2013).  
 
1.3.1.1 RAGE-induced oxidative stress in diabetic complications    
In almost all of the complications mentioned above, RAGE effects were largely mediated through 
oxidative stress-induced inflammation via stress signaling-NF-κB pathways. AGE formation via 
the Millard reaction, polyol pathway, and glucose autoxidation produce a large amount of oxidants 
(Yagihashi et al., 2011). ROS themselves may fuel further generation of AGEs, thereby initiating 
a vicious cycle of oxidative stress (Ramasamy et al., 2005). In addition, RAGE-mediated activation 
of membrane-associated NADPH oxidase generates ROS, which along with the ROS continuously 
generated as by-product of ATP biosynthesis, exacerbate oxidative stress production and 
consumption of the antioxidant defenses (Daffu et al, 2013). Consistent with this, AGEs mediate 
decreased glutathione stores and reduced activity of superoxide dismutase (SOD) and catalase 
(Obrosova 2002; Jiang et al., 2004; Ramasamy et al., 2005). AGEs also stimulate the recruitment 
of RAGE-expressing inflammatory cells and the release of other RAGE ligands, such as HMGB1 
and S100. Therefore, other ligands can amplify RAGE activation and contribute to further cellular 
stress (Daffu et al, 2013). One of the most common downstream consequences of almost all these 
pathways is the activation of NF-κB (Ramasamy et al., 2005). In addition to mediating the 
inflammatory responses, NF-κB leads to the upregulation of RAGE, as the RAGE promoter 
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contains two NF-κB responsive elements, thereby forming a positive feedback loop that 
exacerbates inflammation and tissue injury (Li et al., 2012).   
  
1.3.1.1.1 RAGE and the MAPKs pathway  
As mentioned in the previous sections, there are several stress-activated signaling pathways 
downstream from the RAGE-ligand interaction. The MAPKs signaling cascade is one of those 
pathways. The MAPK family, which consists of three major members, i.e. extracellular-regulated 
kinase (ERK), p38 MAPK, and JNK, is a group of serine/threonine protein kinases that mediate 
proliferation, differentiation, and cell survival in mammalian cells by responding to extracellular 
signals such as growth factors, mitogens, and cellular stress (Morrison 2012). MAPKs are not only 
a well-established downstream signaling molecules of RAGE activation (Yeh et al., 2001), but are 
also involved in cognitive function, synaptic plasticity and glutamate receptor trafficking (Thomas 
and Huganir 2004; Gu and Stornetta 2007; Morel et al., 2018). The MAPK signaling cascade plays 
an important role in NMDA receptor-dependent and independent LTP as well as in the 
metabotropic glutamate receptors (mGluRs)- and NMDA receptor-induced LTD in the 
hippocampus (Li et al., 2007; Izumi et al., 2008; Corrêa and Eales 2012). In addition, MAPK 
signaling cascades are strongly implicated in the control of AMPA receptor trafficking during 
synaptic plasticity (Zhu et al., 2002 and 2005; Huang et al., 2004; Krapivinsky et al., 2004; 
Boudreau et al., 2007). Changes in ERK, p38 and JNK expression and phosphorylation/activity 
are widely reported in models of diabetes (Purves et al., 2001; Chen et al., 2005; Jing et al., 2013; 
Liu et al. 2016; Dalli et al., 2018), which could contribute to the changes in glutamate receptor 
expression and function, synaptic plasticity, and cognitive function in diabetes. Oxidative stress is 
one of the important upstream mediators of MAPKs signaling (Son et al., 2013). Increase in 
oxidative stress, exacerbated by RAGE-ligands binding, is shown to phosphorylate and activate 
various protein kinases in the MAPK signaling pathway (Sharma et al., 2010), which is required 
for the NF-κB activation and the subsequent inflammatory responses and tissue injury (Yeh et al., 
2001) that happens in the diabetic condition.   
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1.3.1.2 RAGE and CNS complications of diabetes 
The physiological functions of RAGE in the CNS remain largely unknown, with few reports 
indicating RAGE involvement in neurite outgrowth and neuronal differentiation during 
development (Wang et al., 2008), although its expression decreases significantly upon cellular 
differentiation (Kim et al., 2012). RAGE is normally expressed at low levels in adult tissues, but 
it is significantly upregulated and activated in a wide variety of cell types under pathological 
conditions, especially at sites where its ligands accumulate (Sorci et al., 2013; Lee and Park 2013). 
The degree of RAGE activation under pathological conditions and its subsequent adverse effects 
seem to be highly dependent on the type of ligand, downstream signaling pathways, and the cell 
type (Sorci et al., 2013).  
RAGE activation within the adult nervous system is shown to mediate neuronal damage and 
dysfunction due to the overproduction of ROS, cytokines and pro-inflammatory molecules, as 
discussed earlier, and therefore it is involved in the pathogenesis of a number of CNS disorders 
such as Parkinson's, Huntington's and Alzheimer's diseases (Piras et al., 2016).  
Since Aβ is a RAGE ligand, significant research has concentrated on the role of RAGE in synaptic 
dysfunction and cognitive impairments in AD-like models, but much less in known about the role 
of RAGE in the CNS complications of diabetes. In the context of AD, for example, AGE-induced 
AD models showed impairments in LTP and memory tasks that were significantly attenuated by 
RAGE blockade (Zhou 2011; Tan et al., 2015). Similarly, hippocampal neurons and brain slices 
treated with AGEs showed decreased synaptic density and impaired hippocampal LTP; effects that 
were largely reduced by genetic RAGE depletion (Zhang et al, 2014). In the context of diabetes, 
long-term diabetes (4 to 8 months) increased expression of RAGE in neurons and glial cells and 
impaired cognitive function (Toth et al., 2006). However, whether/how RAGE led to such 
cognitive impairment remained to be investigated.     
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1.4 Rationale and hypothesis   
RAGE is strongly implicated in the pathogenesis of diabetes. Although the role of RAGE is 
extensively investigated in micro- and macrovascular complication of diabetes, especially 
nephropathy, retinopathy and neuropathy, less is known about the role of RAGE in glucose 
neurotoxicity, as well as in CNS complications of diabetes. In particular, the role of RAGE on 
hippocampal dysfunction, such as impairment in synaptic plasticity and cognitive function, which 
are widely reported in diabetes, remained to be investigated.  
 
We, therefore, hypothesize the following:   
1) RAGE signaling underlies cognitive dysfunction in a mouse model of STZ-induced diabetes 
(Chapter 2).  
2) RAGE signaling alters expression and function of glutamate receptors in high glucose or STZ-
induced diabetic conditions, leading to subsequent impairment in hippocampal synaptic 
transmission (Chapter 3).  
 
The main body of the thesis is written in a “manuscript” style, comprising of two papers (Chapter 
2 and Chapter 3) that have been submitted for publication to peer-reviewed journals.  
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CHAPTER 2 
 
Diabetes induces RAGE-dependent hippocampal spatial memory impairments 
 
2.1 Abstract  
Diabetes is a prevalent metabolic disorder that has long been associated with changes in different 
regions of the brain including the hippocampus. Changes in hippocampal synaptic plasticity and 
subsequent impairment in cognitive functions, such as learning and memory, are well documented 
in animal models of type 1 and type 2 diabetes. It is known that the receptor for advanced glycation 
end products (RAGE) contributes to micro- and macrovascular complications of diabetes. 
However, it is still unknown if RAGE plays a similar role in the development of central nervous 
system (CNS) complications of diabetes. Therefore, we hypothesize that RAGE signaling under 
diabetic condition underlies cognitive dysfunction such as learning and memory impairments in a 
mouse model of STZ-induced diabetes. Control and streptozotocin (STZ)-induced diabetic mice 
from wild-type (WT) and RAGE-KO groups were used for the behavioural experiments. While 
STZ-induced diabetes decreased locomotor activity in the open field (OF) test, it did not affect the 
recognition memory in the novel object recognition (NOR) test in either genotype. Spatial 
memory, however, was impaired in STZ-induced diabetic mice in WT but not in RAGE-KO group 
in both the Barnes maze (BM) and the Morris water maze (MWM) tests. Our findings indicate that 
the parameters associated with locomotor activity and recognition memory were independent of 
RAGE expression in STZ-induced diabetic mice. In contrast, the parameters associated with 
hippocampal-dependent spatial memory were dependent on RAGE expression/signaling.  
_______________________________________ 
Momeni Z, Kiir TAB, Yamamoto Y, Bekar LK, Campanucci VA. Diabetes induces RAGE-dependent 
hippocampal spatial memory impairments. The work in this chapter has been submitted to Physiology and 
Behavior. 
 
Contribution: Momeni Z was responsible for performing all experiments, data analysis, and preparation of 
the manuscript. Kiir helped in the collecting behaviour data; Yamamoto provided the RAGE-KO mice and 
edited the manuscript; Bekar provided access to behavior equipment/software and helped with data 
analysis. 
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2.2 Introduction  
Diabetes is a common metabolic disorder characterized by hyperglycemia due to deficient insulin 
production (type 1) or resistance to insulin action (type 2) or both (Kharroubi and Darwish, 2015). 
Both types of diabetes are associated with chronic complications such as retinopathy, nephropathy, 
angiopathy, and neuropathy (Muriach et al., 2014). Central neuropathy – the effect of diabetes on 
the CNS – manifests as structural and functional alterations in the brain and spinal cord (Selvarajah 
2006; Muriach et al., 2014). Some of these changes are reported in different regions of the brain 
including the hippocampus (Wrighten et al., 2009; Hernández-Fonseca et al., 2009; Seaquist 2010; 
Moheet et al., 2015). A large body of evidence collected from rodent models of diabetes show 
electrophysiological abnormalities in the hippocampus, as well as abnormal hippocampal-
dependent behaviours, especially tasks associated with learning and memory and cognitive 
function (Wrighten et al., 2009; Rostami et al., 2013, Saedi et al., 2016). Studies performed on 
rodent models of type 1 diabetes showed dysfunctional synaptic plasticity, such as impaired long-
term potentiation (LTP) and long-term depression (LTD) (Artola et al., 2005; Kamal et al., 2006) 
and subsequent impairments in spatial memory tasks (Biessels et al., 1998). In addition, type 2 
diabetes is considered as a strong risk factor for the development of Alzheimer’s disease (AD), 
which is characterized by progressive decline of cognitive functions and learning and memory 
impairments (Jia et al., 2017).  
In the search of mechanisms underlying such diabetes-induced cognitive decline, a great attention 
has been paid to RAGE, a member of the immunoglobulin protein family of cell surface molecules 
(Schmidt et al., 2001; Kodl and Seaquist, 2008). Hyperglycemia is linked to the formation of 
advanced glycation end products (AGEs) and the generation of reactive oxygen species (ROS), 
which are both considered as major contributors to the development of nervous system 
complications of diabetes (Yamagishi and Matsui, 2010). Interaction of AGEs with their receptor 
RAGE and the subsequent generation of oxidative stress trigger a cascade of events that induce 
sustained activation of transcription factor nuclear factor kappa beta (NF-κB), a proinflammatory 
gene marker, and further upregulation of RAGE and ROS production, a positive feedback loop 
that intensifies diabetic complications and inflammation-induced tissue injury (Yamagishi and 
Matsui, 2010).  
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The involvement of RAGE in cognitive impairments has been well studied in the context of AD 
(Zhou 2011; Tan et al., 2015; Tan et al., 2015; Lubitz et al., 2016). Exogenous AGEs were shown 
to induce tau hyperphosphorylation at multiple AD-related brain sites both in vitro and in vivo and 
to increase the level of RAGE and impair spatial memory (Zhou 2011; Tan et al., 2015). Similarly, 
poorer memory and higher hippocampal levels of amyloid beta (Aβ) and RAGE were observed in 
AD mice on a high‐AGE diet (Lubitz et al., 2016). These effects were attenuated by RAGE 
blockade (Zhou, 2011; Tan et al., 2015; Hong et al., 2016).  
It remains unclear, however, if RAGE plays a similar role in the development of CNS 
complications of diabetes, particularly cognitive impairments. In the only published study, long-
term diabetic mice (18 to 33 weeks diabetic) demonstrated increased expression of RAGE in 
neurons and glial cells and displayed cognitive dysfunction (Toth et al., 2006). However, whether 
RAGE led to this cognitive deficit was not investigated.  
In addition, although AGEs infusion to the brain, a model used in AD studies, can mimic the 
diabetic state to some extent, it should be taken into consideration that the pathogenesis of 
hyperglycemia includes but is not limited to AGEs. Therefore, there is a lack of information 
regarding RAGE-mediated CNS complications, especially cognitive dysfunction, during a real 
hyperglycemic state in animal models.   
Therefore, in this study, we hypothesize that RAGE signaling during diabetes contributes to 
cognitive dysfunction in STZ-induced diabetic mice. To test this hypothesis, we took advantage 
of a constitutive RAGE-KO mouse model along with the WT mice in the behavioural tests. We 
performed the open field (OF) test to measure locomotor activity and anxiety-like behaviour 
(Seibenhener and Wooten, 2015), followed by the novel object recognition (NOR) test to evaluate 
recognition memory (Antunes and Biala, 2012). Despite the widespread use of NOR test in 
rodents, a strong consensus has not yet developed regarding the brain structures necessary for the 
task performance. For example, although there is agreement about the role of perirhinal cortex in 
NOR performance, there is less agreement on the role of hippocampus (Winters et al., 2008; 
Broadbent et al., 2010; Squire et al., 2010). While some studies show impaired recognition 
memory after hippocampal lesions (Clark et al., 2000; Zola et al., 2000; Broadbent et al., 2010), 
others report spared recognition memory following hippocampal damage (Winters et al. 
2004; Forwood et al. 2005; Mumby et al. 2005). It seems that the degree and type of lesion 
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(permanent vs. temporary/reversible), and retention intervals may play roles in such controversies 
(Broadbent et al., 2004; Albasser et al., 2010; Broadbent et al., 2010).   
In addition to the NOR test, Barnes maze and Morris water maze tests are also used to evaluate 
cognitive functions, especially those related to hippocampal-dependent spatial learning and 
memory (Vorhees and Williams, 2006; Gawel et al., 2019). However, due to undue stress 
associated with water in the MWM test (Harrison et al., 2009), we performed both tests to ensure 
that the results can reflect a more robust and reliable understanding of spatial learning and memory 
performance in the experimental groups.  
Our findings reveal that STZ-induced diabetes reduced locomotor activity in both WT and RAGE-
KO groups. Although STZ-induced diabetes did not lead to significant changes in object 
recognition memory in either genotype, it led to impairment in hippocampal-dependent spatial 
memory in WT but not in RAGE-KO group. These findings constitute novel evidence for the 
contribution of RAGE signaling in hippocampal spatial memory impairments during diabetes.   
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2.3 Experimental Procedures  
2.3.1 Mice and Treatments. To maintain a colony of RAGE-KO mice on a C57BL/6 
background, heterozygous mice were generated by back-crossing RAGE-KO (homozygous) mice 
(Myint et al., 2006) with C57BL/6 WT mice, as previously described (Lam et al., 2018). Genomic 
DNA extraction and polymerase chain reaction were used for genotyping (Myint et al., 2006). 
For type 1 diabetes, male mice (4-6 weeks old) received daily intraperitoneal (i.p.) injection of 50 
mg STZ/kg body weight for three consecutive days, while age-matched controls received citrate 
buffer injections. Blood glucose measurements were obtained one week after the injections using 
a CONTOUR Glucose Meter (Bayer Inc., Toronto, ON, Canada), and animals with blood glucose 
levels >15 mM glucose were considered diabetic. Diabetic animals were kept for one month prior 
to the experiments and blood glucose was measured once more at the end of the one-month period.    
 
2.3.2 Behavioural Experiments. Separate groups of mice were used for each behavioural 
experiment. Mice were brought to the experimental room in their home cages at least half an hour 
before the behavioural experiments to allow them to acclimate to the test environment. The 
experimental room was kept at a controlled temperature (22 ± 2°C). Mice were tested in the OF, 
NOR, BM and MWM. All trials were video-recorded, and the behavioural analysis was carried 
out with the help of the Noldus Ethovision XT software (Leesburg, VA, USA).  
 
2.3.2.1 Open Field Test. The OF apparatus consisted of a solid gray square shaped (40 × 40 cm) 
box. The animals were individually put in the center of the OF apparatus, placed in a standard lit 
room, and were allowed free and uninterrupted movement for 25 minutes. Total time the animals 
spent in the center, total distance traveled, and total movement time were measured (Seibenhener 
and Wooten, 2015).  
 
2.3.2.2 Novel Object Recognition Test. In this test, all groups of mice were subjected to three 
phases: habituation, acquisition and testing, as described previously (Lueptow, 2017). For 
habituation, the mouse was placed into the box and allowed to explore freely for 15 minutes. No 
objects were placed in the box during the habituation phase. On the following day, the acquisition 
27 
 
trial was conducted in which two copies of the same object were placed in the box arena. Mice 
were allowed to explore the two objects for 15 minutes and the time spent exploring each object 
as well as the total exploration time were recorded. After 24 hours, mice were exposed to a 
different copy of the same object used in the acquisition phase and a novel object (not used in the 
acquisition phase) and allowed to explore for 15 minutes. The time spent exploring each object 
and the total exploration time were recorded. The novel object discrimination index was 
calculated as the time spent exploring the novel object divided by the total time spent exploring 
both objects.  
The choice for novel or familiar object was counterbalanced and the position of each object was 
alternated between trials.  
 
2.3.2.3 Barnes Maze Test. The BM consisted of a white circular platform, 100 cm in diameter, 
with 20 equally-spaced holes around the circumference and an escape box fitted under one of the 
holes, placed in a standard lit room with visual cues in the periphery. After habituation, during 
which animals were placed on the maze for a 2-minute undisturbed exploration, mice underwent 
training trials. The sound of a buzzer was used during both acquisition and testing sessions as an 
aversive stimulus to increase the animal’s motivation to escape from the platform during the 2-
minute exploration and was turned off as soon as the animal entered the escape hole. If the 
animal did not find the escape box during the 2-minute exploration, it would be gently guided to 
the escape box, followed by cessation of the buzzer, and allowed to stay there for 1 minute. Mice 
underwent two training trials per day with approximately 15-minue intertrial interval for four 
consecutive days. The amount of time spent to find the escape box (latency) as well as the number 
of incorrect holes explored (errors), escape velocity, and total distance traveled were measured 
during the training sessions. In the probe trial, in which the escape box was not present, the time 
spent in the target quadrant (where the escape box was previously located) was measured. The 
probe trial was conducted 48 hours after the last training day (day 4). Animals were allowed to 
explore the maze for 2 minutes during both training and probe sessions (Gawel et al., 2019).  
 
2.3.2.4 Morris Water Maze Test. A circular maze made of white plastic (120 cm diameter, 80 
cm height) was two thirds filled with water (22 to 23°C) and made opaque by the addition of a 
28 
 
white non-toxic food coloring. Extra-maze landmark cues that were visible from the maze were 
used. In this task, as previously described (Bromley-Brits et al., 2011), mice were first subjected 
to a visible platform phase in which they explored the pool to locate a visible platform. This phase 
can help to exclude mice with visual or locomotor impairments, as well as to habituate them to the 
testing conditions. The following day, mice were tested with a hidden platform task. In this phase, 
a fixed platform was hidden 1 cm below the water surface and was not moved throughout the 
experiments. The entrance point into the maze was changed every trial (we used 4 release points 
every day, one for each trial). Mice received four training trials per day, with approximately 15-
minue intertrial interval, and were allowed to swim for 60 seconds during each trial. If the animal 
did not find the platform during the 60-second period, it would be gently guided to the platform 
and allowed to stay on it for 20 seconds. The training sessions were performed for four consecutive 
days and latency to reach the platform, swimming distance and swimming velocity were measured. 
The probe trial was conducted 48 hours after the last training day (day 4). In this phase, the 
platform was removed and mice were allowed to swim for 60 seconds and the time spent in the 
target quadrant (where the platform was previously located) was measured to evaluate memory 
retention.   
 
2.3.3 Statistical Analysis. All values are reported as mean ± SEM and the level of significance 
was set at 0.05 for all statistical tests performed. For statistical comparisons, we used two-way 
analysis of variance (ANOVA), three-way repeated measures ANOVA, and one-sample t-test as 
indicated in the figure legends. The F values, p values and t values are reported in the figure 
legends. Statistical analyses were carried out with InStat 3.0 or Prism 8.0 (GraphPad Software Inc., 
La Jolla, CA, USA).  
This work was approved by the University of Saskatchewan’s Animal Research Ethics Board 
(Campanucci: protocol 20090082) and adhered to the Canadian Council on Animal Care 
guidelines for humane animal use. 
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2.4 Results 
2.4.1 Induction of diabetes by STZ injection in mice. No significant difference in body weight 
was found between the groups before citrate buffer/STZ treatment, nor in the blood glucose level 
(Figure 2.1). Although both control and STZ-treated mice showed increases in body weight over 
time, STZ-treated mice displayed significant decreases in body weight gain as compared with 
aged-matched controls (Figure 2.1 A). After STZ injection, mice were severely diabetic as 
indicated by elevated blood glucose levels compared with age-matched controls (Figure 2.1 B).  
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Figure 2.1. Body weights and glycemic values of control and STZ-induced diabetic mice. 
Bar graphs summarize the mean ± SEM values of initial and final (A) body weights and (B) blood 
glucose concentrations in control and STZ-induced diabetic mice from WT and RAGE-KO 
groups. “Initial” refers to before STZ or citrate buffer injection and “final” refers to 5 weeks after 
the injections. Values are expressed as the mean ± SEM from WT CNT (n=23), WT STZ (n=28), 
RAGE-KO CNT (n=20), and RAGE-KO STZ (n=25). Means were statistically compared by 
three-way repeated measures ANOVA, followed by Tukey’s multiple comparison test; ***, 
p<0.001. All groups showed significant differences between their final and their initial body 
weight values (A, p<0.001). There was no significant difference between initial and final blood 
glucose values in control mice from both genotypes (B). (T): significant main effect of STZ 
treatment (F(1, 92)=18.44, p<0.001 in A and F(1, 92)=240, p<0.001 in B). There was also a 
significant main effect of time (F(1, 92)=321.9, p<0.001 in A and F(1, 92)=378.8, p<0.001 in B).  
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2.4.2 STZ-induced diabetic mice showed lower locomotor activity as compared with 
controls. The OF test was used to measure locomotor activity and anxiety-like behaviours in STZ-
induced diabetic mice and age-matched controls based on the conflict between a rodent’s natural 
aversion to open areas and its willingness to explore new areas (Schmitt and Hiemke, 1998).  
Our findings show a significant main effect of STZ treatment on the time spent in the center (Figure 
2.2 A), distance traveled (Figure 2.2 B) and total movement time (Figure 2.2 C) in the OF test. 
STZ-induced diabetic mice in both genotypes showed significant reduction in total distance 
traveled and total movement time as compared to their age-matched controls (Figure 2.2 B-C). 
There was a significant genotype difference between WT and RAGE-KO mice in the total time 
spent in the center of the OF (Figure 2.2 A).   
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Figure 2.2. Behavioural parameters in the open field test. (A) Total time the animal spent in 
the center, (B) total distance traveled in the maze and (C) total movement time were measured to 
determine locomotor activity and anxiety-like behaviour in control and STZ-induced diabetic 
mice. Values are expressed as the mean ± SEM from WT CNT (n=21), WT STZ (n=25), RAGE-
KO CNT (n=25), and RAGE-KO STZ (n=30). Means were statistically compared by two-way 
ANOVA, followed by Tukey’s multiple comparison test; *, p<0.05; **, p<0.01. (G): significant 
genotype differences (F(1, 97)=6.01, p<0.05 in A); (T): significant main effect of STZ treatment 
(F(1, 97)=4.19, p<0.05 in A; F(1, 97)=23.32, p<0.001 in B; F(1, 97)=20.36, p<0.001 in C).  
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2.4.3 Recognition memory was not affected by STZ-induced diabetes. The NOR test was 
used to assess recognition memory (Broadbent et al., 2010). Our findings show no significant 
differences in the time spent exploring the two objects during the acquisition phase (Figure 2.3 A). 
There was, however, a significant genotype difference in total exploration time in the acquisition 
phase (Figure 2.3 A). On the testing phase, although all groups explored the novel object for a 
longer period (Figure 2.3 B), the novel object discrimination index was not significantly different 
between control and STZ-induced diabetic mice in either WT or RAGE-KO group or between 
genotypes (Figure 2.3 C). All groups, however, performed above chance (50%) during the testing 
phase (Figure 2.3 C).  
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Figure 2.3. The novel object recognition test. Objects exploration during the (A) acquisition and 
(B) testing day. 1 and 2 in A show the two copies of the same object used during the acquisition 
phase. (C) The discrimination index was calculated as the time spent exploring the novel object 
divided by the total time spent exploring both objects. Values are expressed as the mean ± SEM 
from WT CNT (n=20), WT STZ (n=18), RAGE-KO CNT (n=23), and RAGE-KO STZ (n=28). 
Means were statistically compared by two-way ANOVA, followed by Tukey’s multiple 
comparison test. (G): significant genotype differences (F(3, 170)=9.9, p<0.001 in A). There was a 
significant difference from the chance in WT CNT (t(19)= 2.66; p<0.05), WT STZ (t(17)= 2.37; 
p<0.05), RAGE-KO CNT (t(22)= 4.03; p<0.01) and RAGE-KO STZ (t(27)=2.05; p<0.05) by one 
sample t-test in C.   
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2.4.4 WT STZ-induced diabetic mice showed impairment in hippocampal-dependent 
spatial memory. The BM test was used to evaluate hippocampal-dependent spatial learning and 
memory (Gawel et al., 2019). During the acquisition phase of BM (Figure 2.4), there was a 
significant main effect of STZ treatment on escape latency and velocity, as well as a significant 
difference between the two genotypes in escape latency, number of errors, and velocity (Figure 
2.4 A, C-D).  
On the probe day (Figure 2.5), there was a significant interaction effect between genotype and STZ 
treatment in the percent of time spent in the target quadrant, meaning that the effect of STZ on the 
time spent in the target quadrant differed significantly between the two genotypes (Figure 2.5 A). 
Consistent with this, a significant decrease in the percent of time spent in the target quadrant was 
found in STZ-induced diabetic mice as compared with control in WT, but not in RAGE-KO group 
(Figure 2.5 A). The distance traveled and velocity showed significant decreases in STZ-induced 
diabetic mice from both genotypes (Figure 2.5 B-C).  
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Figure 2.4. Behavioural parameters during the acquisition phase of Barnes maze test. (A) 
Latency to enter the escape hole, (B) number of errors committed before entering the escape hole, 
(C) total distance traveled and (D) escape velocity in control and STZ-induced diabetic mice from 
WT and RAGE-KO groups during the four days of training. Mice received two trials per day. 
Values are expressed as the mean ± SEM from WT CNT (n=13), WT STZ (n=14), RAGE-KO 
CNT (n=11), and RAGE-KO STZ (n=11). Means were statistically compared by repeated 
measures of three-way ANOVA. (G): significant genotype differences (F(1, 94)=18.87, p<0.001 in 
A; F(1, 94)=6.16, p<0.05 in B; F(1, 94)=14.4, p<0.001 in D); (T): significant main effect of STZ 
treatment (F(1, 94)=14.21, p<0.001 in A; F(1, 94)=31.96, p<0.001 in D). There was also a significant 
main effect of time (F(2.957, 278.0)=49.33, p<0.001 in A; F(2.889, 271.5)=21.83 p<0.001 in B; F(2.507, 
235.6)=18.15, p<0.001 in C; F(2.671, 251.1)=7.77, p<0.001 in D).  
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Figure 2.5. Behavioural parameters during the probe trial of Barnes maze test. (A) Percent 
of total time spent in the target quadrant and representative heat maps of the path traveled by CTN 
and STZ-induced diabetic mice from WT and RAGE-KO groups during the probe trial. The arrow 
shows the target quadrant (where the drop box was previously located) and the color scale 
represents the minimum and maximum time spent in a given area. (B) Total distance traveled and 
(C) velocity during the 2 min exploration period. Probe trial was conducted 48 hr after the last 
training day. Values are expressed as the mean ± SEM from WT CNT (n=13), WT STZ (n=14), 
RAGE-KO CNT (n=11), and RAGE-KO STZ (n=11). Means were statistically compared by two-
way ANOVA, followed by Tukey’s multiple comparison test; *, p<0.05; **, p<0.01. (T): 
significant main effect of STZ treatment (F(1, 45)=4.52, p<0.05 in A; F(1, 45)=24, p<0.001 in B; 
F(1, 45)=23.44, p<0.001 in C); (I): significant interaction between genotype and STZ treatment 
(F(1, 45)=4.81, p<0.05 in A).    
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2.4.5 WT STZ-induced diabetic mice showed spatial memory impairment in MWM. 
Similar to the BM, MWM was used to assess hippocampal-dependant spatial learning and memory 
(Vorhees and Williams, 2006). Our data showed no significant difference in latency, distance 
traveled and velocity between control and STZ-induced diabetic mice in either genotype during 
the habituation (visible platform) phase of MWM (Figure 2.6). There was, however, a significant 
main effect of STZ treatment on swimming velocity (Figure 2.6 C).  
During the acquisition (hidden platform) phase of MWM (Figure 2.7), there was a significant main 
effect of STZ treatment on latency (Figure 2.7 A) and a significant difference between the two 
genotypes in latency and swimming velocity (Figure 2.7 A and C).   
On the probe trial (Figure 2.8), there was a significant interaction effect between genotype and 
STZ treatment in the percent of time spent in the target quadrant, indicating that the effect of STZ 
on the time spent in the target quadrant differed significantly between the two genotypes (Figure 
2.8 A). Distance traveled and swimming velocity showed significant differences between the two 
genotypes (Figure 2.8 B-C).  
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Figure 2.6. Behavioural parameters during the visible platform phase of Morris water 
maze. (A) Latency to find the platform, (B) total distance traveled and (C) swimming velocity in 
control and STZ-induced diabetic mice from WT and RAGE-KO groups. Values are expressed as 
the mean ± SEM from WT CNT (n=13), WT STZ (n=10), RAGE-KO CNT (n=10), and RAGE-
KO STZ (n=10). Means were statistically compared by two-way ANOVA, followed by Tukey’s 
multiple comparison test. (T): significant main effect of STZ treatment (F(1, 39)=4.14, p<0.05 in 
C).  
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Figure 2.7. Behavioural parameters during the acquisition phase of Morris water maze. 
(A) Latency to find the platform, (B) total distance traveled, and (C) swimming velocity in control 
and STZ-induced diabetic mice from WT and RAGE-KO groups during the four days of training. 
Mice received four trials per day. Values are expressed as the mean ± SEM from WT CNT (n=13), 
WT STZ (n=10), RAGE-KO CNT (n=10), and RAGE-KO STZ (n=10). Means were statistically 
compared by three-way repeated measures ANOVA. (G): significant genotype differences (F(1, 
168)=19.8, p<0.001 in A; F(1, 168)=76.43, p<0.001 in C); (T): significant main effect of STZ 
treatment (F(1, 168)=4.46, p<0.05 in A). There was also a significant main effect of time (F(2.918, 
490.3)=20.74, p<0.001 in A; F(2.861, 480.7)=13.46, p<0.001 in B).  
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Figure 2.8. Behavioural parameters during the probe trial of Morris water maze. (A) 
Percent of total time spent in the target quadrant and representative heat maps of the path traveled 
by CTN and STZ-induced diabetic mice from WT and RAGE-KO groups during the probe trial of 
the MWM. The arrow shows the target quadrant (where the platform was previously located). (B) 
Total distance traveled and (C) velocity during the 2 min exploration period. The probe trial was 
conducted 48 hr after the last training day. Values are expressed as the mean ± SEM from WT 
CNT (n=13), WT STZ (n=10), RAGE-KO CNT (n=10), and RAGE-KO STZ (n=10). Means 
were statistically compared with two-way ANOVA, followed by Tukey’s multiple comparison 
test; **, p<0.01; ***,  p<0.001; (T): significant main effect of STZ treatment (F(1, 39)=38.31, 
p<0.05 in B); (I): significant interaction between genotype and STZ treatment (F(1, 39)=4.52, 
p<0.05 in A); (G): significant genotype differences (F(1, 39)=57.63, p<0.001 in B; F(1, 39)=6.79, 
p<0.05 in C). 
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2.5 Discussion  
In this study, we provide novel evidence for the involvement of RAGE in hippocampal spatial 
memory impairments under STZ-induced diabetic conditions.  
 
2.5.1 Anxiety-like behaviour and locomotor activity in STZ-induced diabetic mice 
We used the OF test for anxiety-like behaviour, by quantifying the animals’ preference to avoid 
the center of the field in an unknown environment (Choleris et al., 2001). In this regard, STZ is 
shown to induce anxiogenic activity. For instance, STZ-induced diabetic rats showed more 
anxiogenic activity in comparison to non-diabetic rats (Ramanathan et al., 1998), by spending less 
time in central arena of the OF and more time in the closed arms in the elevated plus maze (EPM) 
(Aksu et al., 2012). Anxiety-like behaviours are also shown in STZ-induced diabetic rodents 
subjected to social interaction and zero maze tests (Gupta et al., 2014; Damian et al., 2014; Chu et 
al., 2017). Changes in neurotransmitters, such as gamma-aminobutyric acid (GABA) and 
monoamines in different brain regions and increases in the hypothalamic–pituitary–adrenal axis 
(HPA) activity and glucocorticoid levels are shown to contribute to diabetes-associated anxiety in 
many studies (Ramanathan et al., 1998; Duarte et al., 2000; Gomez et al., 2003; Antony et al., 
2010; Kumar et al., 2010; Shpakov et al., 2011; Torres et al., 2013; Gupta et al., 2014). In our 
study, STZ treatment caused a significantly decreased time spent in the center of the OF, which 
may indicate an increase in anxiety-like behaviour. However, a significant decrease in locomotor 
activity, and not necessarily a change in anxiety-like behaviour, might have contributed to the 
decrease in the time spent in the centre of the OF in our study.  
Our findings also showed a significant genotype difference in the time spent in the centre of the 
OF. Although a previous study showed no significant difference between WT and RAGE-KO mice 
in anxiety-like behaviour in the OF test (Sakatani et al., 2009), the two by two factorial design, i.e. 
intervention of an additional factor (STZ) in our experimental design, might explain discrepancy 
between the two studies.  
Our results also demonstrated a significant effect of STZ treatment on decreased distance traveled 
and movement time in STZ-induced diabetic mice in both genotypes in the OF test, which is 
consistent with other studies that reported a significant reduction in locomotor activity, exploratory 
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behaviour, and distance traveled in the OF, passive avoidance, NOR, and the activity cage tests in 
response to STZ-induced diabetes (Mayer et al., 1990; Haider et al., 2013; Bădescu et al., 2016b; 
Bensaoula et al., 2016;  Patel et al., 2016; El-Marasy et al., 2017). Hyperglycemia-induced 
decreases in striatal cholinergic receptor expression and function as well as glutamate toxicity and 
cellular damage in the cerebellum were associated with impaired locomotor activity in STZ-
induced diabetes (Sherin et al., 2012; Nagayach et al., 2014).  
Since our findings show similar trends in the parameters associated with locomotor activity in both 
WT and RAGE-KO groups, as reported previously (Sakatani et al., 2009), we suggest that these 
parameters are independent of RAGE expression/signaling.   
 
2.5.2 Novel object recognition memory  
In rodents, the NOR test has been widely used for assessing recognition memory (Broadbent et al., 
2009) based on the tendency of the animal to spend more time exploring a novel object than a 
familiar one (Lueptow, 2017). STZ-induced diabetes from 8 to 10 weeks showed a recognition 
memory deficit in the NOR test (King et al., 2013; Jabbarpour et al., 2014; Patel et al., 2016). The 
results of our 5-week STZ-induction of diabetes in mice performing the NOR test, however, 
showed no significant difference between control and STZ-induced diabetic mice in either WT or 
RAGE-KO group in the novel object discrimination index during either 5 min or 15 min 
exploration.   
As mentioned earlier, reports are controversial regarding the role of the hippocampus in 
recognition memory. Although hippocampus is suggested to play an important role in recognition 
memory encoding and consolidation (Cohen et al., 2013), other brain regions, including the 
perirhinal regions, are reported to play more important and/or more direct roles (Winters et al., 
2008). It is suggested that the hippocampus is involved in object recognition when spatial or 
contextual components are involved in the task (Winters et al. 2004; Forwood et al. 2005). It is 
also suggested that the hippocampus may play a time-limited role in object recognition memory 
(Broadbent et al., 2010). Although the role of the hippocampus in recognition memory remains 
controversial, our result showing a spared recognition memory during potential hippocampal 
damage by STZ-induced diabetes (Pamidi et al., 2012) suggest minimal or lack of hippocampal 
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involvement in the task and/or larger involvement of other brain regions, such as perirhinal 
regions, or the possibility of compensatory mechanisms by other structures within the medial 
temporal lobe (MTL) (Cohen et al., 2013).  
Regardless of the brain areas involved, the role of RAGE in recognition memory has not been 
studied so far. Since our data show a similar trend in the parameters associated with recognition 
memory in both WT and RAGE-KO groups, we can infer that recognition memory is independent 
of RAGE expression/signaling, at least during the period our experiments lasted.  
 
2.5.3 Hippocampal-dependent spatial learning and memory  
The central role of the hippocampus in spatial learning and memory is well established (Moser et 
al., 2008; Pilly and Grossberg, 2012), including spatial navigation in animals (Eichenbaum, 2017). 
Hippocampal lesions in animals were associated with impaired performance on spatial tasks 
(Broadbent et al., 2006; Clark et al., 2007).  
In animal models of diabetes, hippocampal-dependent spatial learning and memory showed 
impairments following 1, 2, 4, and 12 weeks of STZ-induced diabetes in the MWM (Baydas et al., 
2003b; Babri et al., 2013; Ghasemi et al., 2016), as well as in the BM test (Jolivalt et al., 2010; 
Enhamre-Brolin et al., 2013; King et al., 2013; Anderson et al., 2014; Tender and Razdan 2017). 
Furthermore, STZ-induced diabetic rats showed learning deficits in the hippocampal-dependent 
version of the MWM, while this effect was absent in a non-hippocampal dependent version of the 
maze (Biessels et al., 1998; Stranahan et al., 2008). Studies performed on STZ-induced diabetic 
animals suggest that cognitive impairments elicited by diabetes might result from 
electrophysiological dysfunction in the CA1 region of the hippocampus, particularly defects in the 
expression of LTP (Biessels et al., 2002), changes in the expression and function of glutamate 
receptors (Gispen and Biessels, 2000; Trudeau et al., 2004), alteration in neurotransmitter 
synthesis or release (Trudeau et al., 2004), morphological changes such as decreased length of 
apical dendrites as well as reduced number of apical branch points of CA3 pyramidal neurons 
(Magarinos and McEwen, 2000), and decreased hippocampal neurogenesis (Stranahan et al., 
2008).  
45 
 
Consistent with the behavioural findings of the above-mentioned studies, our results show a 
significant effect of STZ on spatial cognitive performance. The results of our spatial behavioural 
tasks show spatial memory impairment in WT STZ-induced diabetic mice in both BM and MWM 
tests. The significant interaction between STZ treatment and the genotype in the time spent in the 
target quadrant in both of these tests indicates that the effect of STZ on spatial memory differed 
significantly between the two genotypes, suggesting that hyperglycemia does not affect the spatial 
memory performance in the RAGE-KO group, further supporting the involvement of RAGE 
expression and/or signaling in cognitive dysfunction under diabetic conditions.  
Unfortunately, the role of RAGE in initiating and/or exacerbating cognitive abnormalities in 
diabetes has not been well explored yet. In one study, D-ribosylation-derived AGEs formation 
caused spatial learning and memory impairment in the MWM test through RAGE-dependent 
astrocytic inflammation (Han et al., 2014). An elevated serum AGE level was associated with a 
higher risk of mild cognitive impairment (MCI) in type 2 diabetic patients (Wang et al., 2016). 
Similarly, serum AGEs and RAGE showed an increase in the circulation of MCI elderly diabetic 
patients compared to controls (Gorska-Ciebiada et al., 2015), suggesting the AGE-RAGE system 
as a potential contributor to the development of cognitive decline in diabetes. Involvement of 
RAGE in cognitive dysfunction, however, has been more investigated in the context of AD. 
Double transgenic mice, with mutant amyloid precursor protein (mAPP) and targeted neuronal 
overexpression of RAGE, displayed early abnormalities in spatial learning and memory before 
such changes were observed in mAPP mice (Arancio et al., 2004). In contrast, transgenic mice 
with a dominant-negative form of RAGE targeted to neurons crossed with mAPP mice showed 
preservation of spatial learning and memory (Arancio et al., 2004). Exogenous AGEs were shown 
to induce tau hyperphosphorylation and spatial memory deficit through RAGE-mediated pathways 
(Zhou, 2011), and RAGE blockade was able to significantly attenuate memory impairments in 
AGE-induced AD models (Tan et al., 2015). Direct interaction of neuronal RAGE with its ligands 
can provoke oxidative stress and activation of mitogen-activated protein kinase (MAPK) signaling 
pathways, which subsequently mediate synaptic deficits and cognitive dysfunction (Yan et al., 
2012). In addition to neuronal RAGE, RAGE-dependent signaling in microglia also contributed to 
neuroinflammation, accumulation of Aβ, and impaired learning and memory in a mouse model of 
AD (Fang et al., 2010). Although more research is still required regarding the role of RAGE in the 
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context of CNS complications of diabetes, our constitutive RAGE-KO model seems to be spared 
from STZ-induced diabetic effect on spatial memory function.  
Our spatial behavioural tasks also showed changes in the velocity and distance traveled in response 
to STZ treatment. Although STZ-induced diabetic mice showed lower velocity and distance 
traveled during the probe trial of the BM test, the opposite trend was observed in the MWM test. 
The lower velocity and distance traveled in STZ-induced diabetic mice in the BM test is 
compatible with the lower locomotor activity observed in the open field test. However, the higher 
velocity and distance traveled in STZ-induced diabetic mice in the MWM can be partly due to the 
higher anxiety level of this group as compared with age-matched controls, probably due to the 
higher tendency of anxious animals to avoid water (Bondarenko, 2017). This finding also supports 
the results of the OF test, suggesting that less time spent in the centre of the OF in STZ-induced 
diabetic mice can be due to anxiety-like behaviour and not merely impairment in locomotor 
activity. Interestingly, RAGE-KO mice, which showed significantly higher anxiety-like behaviour 
in the OF test as compared to WT mice, displayed significantly more distance traveled and velocity 
during the probe trial in the MWM when compared to the age-matched WT mice. The latter is 
consistent with a report showing that RAGE deletion causes hyperactivity and increased home 
cage activity in mice (Sakatani et al., 2009).     
It also needs to be mentioned that the NOR test showed a significant genotype difference in the 
total exploration time during the acquisition phase of the task. As there is no study available 
regarding the role of RAGE in exploratory behaviours, especially those in the NOR test, we cannot 
explain at this point the effect of genotype we observed in the acquisition phase and not the testing 
phase of the task. If it is due to, again, anxiety-like phenotype, as observed in the OF and the MWM 
tests, or other factors such as hyperactivity (Sakatani et al., 2009) of the RAGE-KO mice needs 
further investigations.   
In conclusion, although the effect of STZ on cognitive function, such as learning and memory 
impairments, is widely reported in diabetes, the role of RAGE in these effects has never been 
investigated and, to the best of our knowledge, this is the first study that shows the involvement of 
RAGE signaling in hippocampal-dependent spatial memory dysfunction under STZ-induced 
diabetic condition.  
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CHAPTER 3 
 
RAGE signaling is required for AMPA receptor dysfunction in the hippocampus of 
diabetic mice 
3.1 Abstract  
Diabetes in humans has been associated for a long time with cognitive dysfunction. In rodent 
animal models, cognitive dysfunction can manifest as impaired hippocampal synaptic plasticity. 
Particular attention has been concentrated on the receptor for advanced glycation end products 
(RAGE), which is implicated in multiple diabetic complications involving the development of 
vascular and peripheral nerve abnormalities. In this study, we hypothesize that RAGE signaling 
alters glutamate receptor function and expression, impairing synaptic transmission in the 
hippocampus. Using preparations of hippocampal slices from male mice, we show a RAGE-
dependent decrease in long-term potentiation (LTP) and an increase in paired-pulse facilitation 
(PPF) following STZ-induced diabetes. Consistently, in hippocampal cultures from male and 
female neonatal mice, high glucose caused a RAGE-dependent reduction of AMPA- but not 
NMDA-evoked currents, and an increase in cytosolic reactive oxygen species (ROS). Hippocampi 
from diabetic WT mice showed increased RAGE expression concomitant with a decrease of both 
expression and phosphorylation (Ser 831 and 845) of the AMPA GluA1 subunit. We found these 
changes correlated to activation of the MAPK pathway, consistent with increased detection of total 
p38, pp38, nuclear factor-kappaB (NF-κB), and decreased pJNK and its kinase, pMEK7. As no 
changes in expression or phosphorylation of regulatory proteins were observed in hippocampi 
from diabetic RAGE-KO mice, we report a RAGE-dependent impairment in the hippocampi of 
diabetic WT mice, with reduced AMPA receptor expression/function and LTP deficits. 
 __________________________ 
Momeni Z, Urban R, Yamamoto Y, Campanucci VA. RAGE signaling is required for AMPA receptor 
dysfunction in the hippocampus of diabetic mice. The work in this chapter is under review by Physiology 
and Behavior.  
Contribution: Momeni was responsible for preforming all experiments, data analysis, and preparation of 
the manuscript. Urban helped in collecting electrophysiology data; Yamamoto provided the RAGE KO 
mice and edited the manuscript.  
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3.2 Introduction  
Diabetes is a metabolic disorder characterized by chronic hyperglycemia due to the impaired 
production, secretion (type 1), or action of insulin (type 2; Ozougwu et al., 2013), affecting several 
organ systems, including the brain (Watkins and Thomas, 1998). Studies have indicated that both 
types of diabetes, type 1 and type 2, induce deleterious changes in the hippocampus leading to 
cognitive dysfunction, including learning and memory impairments (Saedi et al., 2016). 
streptozotocin (STZ)-induced type 1 diabetic rats, as well as other rodent models of type 1 (e.g. 
alloxan-induced) and type 2 (e.g. db/db mice and Zucker rat) diabetes, have shown dysfunctional 
hippocampal plasticity and impairments in cognitive performance (Wrighten et al., 2009; Rostami 
et al., 2013).  
Hyperglycemia-induced oxidative stress is proposed as one of the main mechanisms underlying 
such diabetes-related complications (Giacco  and Brownlee, 2010). Oxidative stress is caused by 
the accumulation of ROS, which are usually generated by the mitochondria as by-products of ATP 
biosynthesis, as well as by cytoplasmic enzymes and non-enzymatic glucose oxidation (Russell et 
al., 2002). One of the non-enzymatic glucose metabolic pathways with critical importance in 
diabetes is the formation of advanced glycation end products (AGEs) (Nass and Simm, 2009). 
AGEs are formed by the non-enzymatic reaction of sugar with amino groups on macromolecules 
(Nass and Simm, 2009) and this reaction, which occurs in our bodies increasingly as we age, is 
exacerbated under diabetic conditions due to the increased availability of glucose (Nass and Simm, 
2009). AGEs bind to their receptor, RAGE, which is a member of the immunoglobulin protein 
family of cell surface molecules (Fang et al., 2010). Findings that RAGE interacts with multiple 
ligands and that some of these ligands accumulate under diabetic conditions (Yao et al., 2010) 
support the possibility of RAGE involvement in the development of diabetic complications 
(Ramasamy et al., 2011). RAGE activation induces oxidative stress and increases expression of 
inflammatory mediators (Granic et al., 2009). Thus, while hyperglycemia ignites the generation of 
AGEs and their subsequent interaction with RAGE, the interplay of RAGE with other ligands 
further amplifies oxidative stress and promotes RAGE up-regulation, a cycle that intensifies 
diabetic complications and inflammation-induced tissue injury (Bartsch et al., 2015).  
Electrophysiological studies in STZ-induced diabetic rodents have revealed deficits in the 
generation of LTP, as a measure of impaired learning and memory processes (Biessels et al., 1998; 
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Lynch, 2004; Artola et al., 2005). Furthermore, STZ-induced and spontaneously diabetic animals 
have shown changes in the expression and/or function of NMDA and AMPA subtypes of 
glutamate receptors (Trudeau et al., 2004; Sasaki-Hamada et al., 2012), which play a critical role 
in induction and maintenance of LTP (Riedel et al., 2003). The strength of individual excitatory 
synapses is determined in part by the number of AMPA receptors present at synapses. Changes in 
the regulation and targeting of synaptic AMPA receptors reduce capacity of synaptic transmission 
and plasticity (McCormack et al., 2006), which may underlie cognitive impairment (Thomas and 
Huganir, 2004; Stornetta and Zhu, 2011). In diabetes it remains unclear, however, if changes in 
synaptic AMPA receptors and RAGE signaling are linked as part of the CNS pathology associated 
with the disease. 
In this study, we hypothesize that RAGE signaling in diabetic conditions (in vitro high glucose or 
in vivo STZ-induced diabetes) interferes with the expression and function of synaptic glutamate 
receptors in the hippocampus, leading to deficits in synaptic transmission. Our findings show that 
hyperglycemia decreases the expression of the AMPA GluA1 subunit and its phosphorylation in 
WT but not in RAKE-KO mice. We also show that RAGE expression is required for LTP 
impairment in hippocampal slices from STZ-induced diabetic mice and for changes in expression 
and/or phosphorylation of signaling proteins including NF-κB, p38, and JNK, which are all 
downstream from RAGE. In particular, we found reduced phospho-JNK (pJNK), accompanied by 
a reduction in its kinase phospho-MEK7 (pMEK7) and an increase in phospho-p38 (pp38), which 
correlated with reduction in hippocampal neuronal excitability. Taken together, these findings 
constitute novel evidence for the contribution of RAGE signaling in abnormal hippocampal 
synaptic transmission in diabetes.  
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3.3 Materials and Methods 
3.3.1 Animals  
Heterozygous mice generated by back-crossing RAGE-KO (homozygous) mice (Myint et al., 
2006) with C57BL/6 wild-type (WT) mice were used to maintain a colony of RAGE-KO mice on 
a C57BL/6 background, as previously described (Lam et al., 2018). Genomic DNA extraction and 
polymerase chain reaction were used for genotyping ( Myint et al., 2006). 
Male and female neonate mice [postnatal day 0 (P0)–P2] were used for in vitro experiments, and 
4-6 weeks old male mice were used for STZ induction of diabetes. For STZ treatment, mice 
received daily i.p. injections of 50 mg STZ/kg body weight for three consecutive days, while age-
matched controls received citrate buffer injections. Blood glucose measurements were obtained 10 
days after injections using a CONTOUR Glucose Meter (Bayer Inc., Toronto, ON, Canada), and 
animals with blood glucose levels >15 mM were considered diabetic. Diabetic animals were kept 
for one month prior to the experiments, and blood glucose was measured once more when the 
animals were sacrificed. Determination of serum insulin level was performed using a mouse 
insulin enzyme-linked immunosorbent assay (ELISA) kit (Mercodia, Uppsala, Sweden) according 
to the manufacturer’s instructions. Insulin levels were measured at the end of the one-month period 
when the animals were sacrificed.  
 
3.3.2 Primary hippocampal culture. Hippocampal neurons were cultured from neonatal (P0-
P2) mice as previously described (Falzone and Stokin, 2012). Briefly, hippocampal regions were 
dissected from WT and RAGE-KO mice and incubated in a mixture of papain (45 units) in 
phosphate-buffered saline (PBS), enriched with 0.05% of DNase, for 20 minutes at 37˚C, followed 
by gentle trituration in 10% fetal bovine serum (FBS) in Dulbecco’s modified Eagle’s medium. 
Cells were grown on poly-D-lysine-coated coverslips at 37˚C under 5% CO2 in 500 mM L-
glutamine and custom neurobasal medium (5 mM glucose) supplemented with B27. Cultured 
neurons were maintained in medium containing either 5 mM glucose (control) or 25 mM glucose 
(high glucose) for 1-2 weeks.  
To monitor neuronal loss, cultured hippocampal neurons were labelled with annexin V conjugated 
with fluorescein isothiocyanate (FITC) and propidium iodide (PI), using annexin V-FITC 
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apoptosis detection kit (Sigma-Aldrich). As a positive control, some cells were exposed to 1 mM 
hydrogen peroxide (H2O2) for 2 hours to induce cell death. Images were collected with an 
AxioObserver inverted microscope and Zen software (Carl Zeiss, Oberkochen, Germany), and 
results are presented as percentage of positive cells to total cells counted.  
 
3.3.3 Intracellular ROS levels. ROS level changes were evaluated in experimental groups (Lam 
et al., 2018) using the ROS-sensitive dye CM-H2DCFDA (Molecular Probes, Eugene, OR, USA), 
and H2O2 (100 µM for 24 hr.) was used as a positive control (Xu et al., 2012). Cultures were 
incubated for one hour at 37°C with medium containing CM-H2DCFDA (10 μM) and subsequently 
washed three times with control extracellular solution (see below). The cultures were then placed 
on the stage of an inverted microscope (AxioObserver, Carl Zeiss, Germany) and viewed through 
a 40x (1.3 numerical aperture) Plan Neofluor oil-immersion objective lens (Zeiss) at 37oC. To 
obtain fluorescent images, we excited the cultures with 470 nm wavelength light using a Colibri 
2.0 LED illumination system (Zeiss) and collected 510-550 nm wavelength emissions with an 
AxioCam camera (Zeiss) controlled by AxioVision v4.8 software (Zeiss). For each neuron 
recorded, the background fluorescence was subtracted from its mean fluorescence intensity. 
 
3.3.4 Whole-cell patch-clamp electrophysiology. Cultured hippocampal neurons maintained 
for 1–2 weeks in control and high glucose were used for whole-cell patch-clamp recording. An 
Axopatch 200B amplifier (Molecular Devices, Palo Alto, CA) equipped with a 1 GΩ cooled head-
stage feedback resistor and a Digidata 1400A analog-to-digital converter (Molecular Devices) 
were used for current and voltage clamp protocols. pClamp 10 (Molecular Devices) and Origin 
9.0 software (OriginLab Corporation, Northampton, MA, USA) were used for data acquisition and 
analysis. Patch pipettes were made from thin-wall borosilicate glass capillaries (World Precision 
Instruments, FL, USA) and were pulled using a vertical puller (PC 10; Narishige Scientific 
Instrument Lab., Tokyo, Japan). Pipette tips were polished with a microforge (Narishige) to a final 
resistance of 3–8 MΩ when filled with intracellular recording solution containing (in mM): 65 KF, 
55 KAc, 5 NaCl, 0.2 CaCl2, 1 MgCl2, 10 EGTA, 2 MgATP, and 10 HEPES (all from Sigma-
Aldrich) at pH=7.2. Cultured neurons were perfused continuously at 1 mL/min with control 
extracellular solution consisting of (in mM): 140 NaCl, 5.4 KCl, 25 HEPES, 5 glucose, and 5 
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μg/mL phenol red (all from Sigma-Aldrich) at pH = 7.4. NMDA (50 µM)/glycine (1 µM)- or 
AMPA (50 µM)-containing extracellular solution was delivered at a perfusion rate of 1 mL/min 
using a fast-step pressurized perfusion system.  
 
3.3.5 Hippocampal slice electrophysiology. Acute hippocampal slices were prepared from 
control and STZ-induced diabetic mice (Pitcher et al., 2011). Briefly, parasagittal hippocampal 
slices (300 μm) were prepared from the hippocampi of WT and RAGE-KO mice, using a vibrating 
tissue slicer (VTS1200S, Vibram Instruments, Germany) and were placed in a holding chamber 
containing artificial cerebrospinal fluid (aCSF) at 32°C for 30 min and then at room temperature 
for at least 1 h before recordings. A single slice was then transferred to the recording chamber and 
superfused with aCSF composed of 124 mM NaCl, 2.5 mM KCl, 1 mM NaH2PO4, 1.3 mM MgCl2, 
11 mM d-glucose, 26 mM NaHCO3, and 2 mM CaCl2 (all from Sigma-Aldrich), saturated with 
95% O2 (balance 5% CO2) at 2 mL/min at room temperature, pH 7.4, 315–325 mOsm. Synaptic 
responses were evoked by stimulating Schaffer collateral afferents using bipolar tungsten 
electrodes located ~50 μm from the pyramidal cell body layer in CA1. Extracellular field excitatory 
postsynaptic potentials (fEPSPs) were recorded using aCSF-filled glass micropipettes placed in 
the stratum radiatum 60–80 μm from the cell body layer. Stimulus-response curves were used to 
establish a stimulation voltage that would induce a 60–70% maximal fEPSP amplitude. LTP was 
induced by theta burst stimulation (TBS) consisting of 15 bursts of four pulses at 100 Hz, delivered 
to Schaffer collateral afferents at an interstimulus interval of 200 ms. In LTP experiments, the 
value of fEPSP amplitude from the 10 min period before TBS was defined as baseline (100%) 
although the recording was continued for 20 min until a stable baseline was reached. For PPF, we 
used a range of interstimulus intervals (25 ms to 800 ms), and the PPF ratio was calculated by 
dividing the amplitude of the second fEPSP by that of the first fEPSP. We averaged data from five 
paired-pulse stimulations for each slice. Raw data were amplified using a MultiClamp 700B 
amplifier and a Digidata 1440A acquisition system and were analyzed using pClamp 10 
(Molecular Devices) and Origin 9.0 software (OriginLab Corporation, Northampton, MA, USA).  
 
3.3.6 Western blotting. We used whole extracts from both cultured neurons and hippocampal 
tissues collected from adult mice. For the whole-cell extracts from cultured neurons, cultures 
maintained for 1–2 weeks in control and high-glucose conditions were lysed using a 1% Nonidet 
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P-40 (NP-40) lysis buffer containing a protease and phosphatase inhibitor cocktail. At least 3 
replicas were used per condition (control and high glucose) for both WT and RAGE-KO mice. 
Each replica was generated from 5 pups. For hippocampal tissues, whole hippocampi of control 
and STZ-induced diabetic mice were homogenized in ice-cold CelLytic™ MT Cell Lysis Reagent 
(Sigma-Aldrich) containing a protease and phosphatase inhibitor cocktail. At least 3 replicas were 
used per condition (CNT or STZ) for both WT and RAGE-KO mice. Equal amounts of protein 
were loaded per group, separated on 12% SDS polyacrylamide gels and then electrotransferred 
onto a nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA, USA). Membranes were 
incubated overnight at 4°C with the following primary antibodies: rabbit anti-GluN1, anti-
GluN2A, anti-GluN2B, anti-GluN2C, anti-GluN2D, anti-GluN3A, and anti-GluN3B (1:1000, 
NMDA Receptor Antibody Explorer Kit, Alomone Labs); rabbit anti-GluA1, anti-GluA2, anti-
GluA3 and anti-GluA4 (1:1000, AMPA Receptor Antibody Explorer Kit, Alomone Labs); and 
rabbit anti-phospho-GluA1 (Ser831 and Ser845) (1:1000, Abcam), rabbit anti-RAGE (1:1000; 
Abcam), rabbit anti-NF-κB p65 (1:1000, Abcam), rabbit anti-ADAM10 (1:1000, Abcam), rabbit 
anti-Erk1/2 and anti-phospho Erk1/2 (Thr202/Thr204) (1:1000, Cell Signaling), rabbit anti-p38 
MAPK and anti-phospho-p38 MAPK (Thr180/Thr182) (1:1000, Cell Signaling), rabbit anti-JNK 
and anti-phospho JNK (Thr183/Thr185) (1:1000, Cell Signaling), rabbit anti-phospho MKP1/2 
(Ser296 and Ser318) (1:500, Thermofisher Scientific), rabbit anti-phospho-MEK7 (Ser277 and 
Thr275) (1:1000; Abcam) and mouse anti-α-tubulin (1:2000; Sigma); followed by horseradish 
peroxidase-conjugated goat anti-rabbit or goat anti-mouse secondary antibodies (1:20000; Bio-
Rad Laboratories). Protein signals were visualized using enhanced chemiluminescence reagents 
(Bio-Rad) and quantified by densitometry using ImageJ software (NIH, Bethesda, MD, USA).  
 
3.3.7 Experimental design and statistical analysis. All values are reported as mean ± SEM and 
the level of significance was set at 0.05 for all statistical tests performed. To compare two means, 
we used parametric Student’s t-tests or non-parametric Mann-Whitney U tests as indicated in the 
figure legends. To compare multiple means, we used two-way ANOVA and three-way repeated 
measures ANOVA as indicated in the table and figure legends. Statistical analyses were carried 
out with InStat 3.0 or Prism 8.0 (GraphPad Software Inc., La Jolla, CA, USA). Details for 
statistical tests used are provided within figure legends. Each n number is indicated in the figure 
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legends. All sample sizes and experimental designs were based on previously published data from 
our lab and similar experiments in the field.  
This work was approved by the University of Saskatchewan’s Animal Research Ethics Board 
(Campanucci: protocol 20090082) and adhered to the Canadian Council on Animal Care 
guidelines for humane animal use.   
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3.4 Results 
3.4.1 Induction of diabetes by STZ injection in mice 
After STZ injection, mice were severely diabetic as indicated by elevated blood glucose and low 
circulating insulin levels (below detectable range for ELISA, i.e., <0.2 µg/L) compared with age-
matched controls in both genotypes (Table 3.1). Body weights indicate that, even though all mice 
gained weight between initial and final measurements, STZ-treated mice from both genotypes 
displayed significantly less body weight gain as compared with their aged-matched controls (Table 
3.1). The lack of significant differences in blood glucose and insulin levels between genotypes, 
confirms that WT and RAGE-KO mice had similar basal levels and that STZ induced a similar 
diabetic state in both genotypes, as previously shown (Shoji et al., 2006; Soro-Paavonen et al., 
2008; Hamada et al., 2010).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
56 
 
Table 3.1. Glycemic and body weight values.  
 
Blood glucose concentrations, body weights, and insulin levels in nondiabetic control (CNT) and 
STZ-induced diabetic mice from WT and RAGE-KO groups. Measurements were taken before 
STZ or citrate buffer injections (Initial) and/or at the end of the experiment (Final). Means were 
statistically compared by three-way repeated measures ANOVA, followed by Tukey's multiple 
comparisons test. Significant main effect of STZ treatment on blood glucose: F(1, 56)=424.3, 
p<0.001; and on body weight: F(1, 56)=37.59, p<0.001. Significant main effect of time on blood 
glucose: F(1, 56)=520.4, p<0.001; and on body weight: F(1, 56)=227.7, p<0.001. 
 
 
 
 
 
 
Groups Blood glucose (mM) Bodyweight (g)  Insulin (µg/L) 
 
Initial Final Initial Final Final 
WT CNT 
 
9.5 ± 0.26 
(n=18) 
 
(n)(n) 
10.29 ± 0.28 
(n=18) 
16.6 ± 0.57 
(n=18) 
26.95 ± 0.4 
(n=18) 
2.41 ± 0.63 
(n=11) 
WT STZ 
 
9.4 ± 0.24 
(n=14) 
30.51 ± 1.29  
(n=14) 
15.37 ± 0.77 
(n=14) 
20.83 ± 0.91  
(n=14) 
< 0.2  
(n=7) 
RAGE-KO CNT 
 
8.96 ± 0.32 
(n=15) 
 
10.56 ± 0.42 
(n=15) 
18.18 ± 0.46 
(n=15) 
25.9 ± 0.57 
(n=15) 
2.77 ± 0.87 
(n=9) 
RAGE-KO STZ 
 
9.21 ± 0.17 
(n=13) 
29.95 ± 1.48  
(n=13) 
17.23 ± 1.01 
(n=13) 
21.16 ± 0.88  
(n=13) 
< 0.2  
(n=7) 
 
Blood glucose 
Initial WT STZ vs. Final WT STZ: p<0.001 
Initial RAGE-KO STZ vs. Final RAGE-KO STZ: p<0.001 
Final WT CNT vs. Final WT STZ: p<0.001 
Final RAGE-KO CNT vs. Final RAGE-KO STZ: p<0.001 
Bodyweight 
Initial WT CNT vs. Final WT CNT: p<0.001 
Initial WT STZ vs. Final WT STZ: p<0.001 
Initial RAGE-KO CNT vs. Final RAGE-KO CNT: p<0.001 
Initial RAGE-KO STZ vs. Final RAGE-KO STZ:  p<0.01 
Final WT CNT vs. Final WT STZ: p<0.001 
Final RAGE-KO CNT vs. Final RAGE-KO STZ:  p<0.001 
57 
 
3.4.2 STZ-induced diabetes caused impairment in hippocampal synaptic plasticity in WT, 
but not in RAGE-KO, mice  
To study the effect of diabetes on synaptic strength in the presence and absence of RAGE 
expression, we examined hippocampal synaptic plasticity in brain slices from STZ-induced 
diabetic WT and RAGE-KO mice. We recorded fEPSPs from hippocampal slices of control and 
STZ-induced diabetic mice from both genotypes. We observed a significant main effect of STZ 
treatment on TBS-induced LTP as well as a significant difference between the two genotypes 
(Figure 3.1). There was also a significant interaction between STZ treatment and the genotype, 
indicating that the effect of STZ on LTP differed significantly between the two genotypes. 
Consistent with this, the TBS-induced LTP was significantly lower in STZ-induced diabetic WT 
mice, but not in STZ-induced diabetic RAGE-KO mice (Figure 3.1). To evaluate whether diabetes 
also induces presynaptic changes, we quantified PPF. The PPF ratio showed a significant increase 
at the 25 ms interval in STZ-induced diabetic WT mice, but, again, not in RAGE-KO mice (Figure 
3.2). These findings demonstrate that under diabetic conditions, changes in hippocampal synaptic 
plasticity require RAGE expression and involve both pre- and postsynaptic components. 
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Figure 3.1. RAGE-dependent synaptic plasticity impairment in STZ-induced diabetic 
mice. (A) Representative traces and (B) time-course of field EPSP amplitude in slices from control 
(CNT) and STZ-induced diabetic mice in WT and RAGE-KO groups expressed as the percentage 
of baseline. (C) Bar graphs summarizing LTP during the last 50-min period after TBS delivery 
in control (CNT) and STZ-induced diabetic groups. Values expressed as the mean ± SEM from 
WT CNT (n=9 slices from 5 mice), WT STZ (n=10 slices from 5 mice), RAGE-KO CNT (n=8 
slices from 4 mice) and RAGE-KO STZ (n=9 slices from 5 mice). Means were statistically 
compared by two-way ANOVA followed by Sidak’s multiple comparison test; *** p<0.001. 
(G): significant genotype differences (F(1, 194)=1475, p<0.001); (T): significant main effect of 
STZ treatment (F (1, 194) =105.2, p<0.001); (I): significant interaction between genotype and STZ 
treatment (F(1, 194)=145.6, p<0.001).  
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Figure 3.2. RAGE-dependent PPF impairment in STZ-induced diabetic mice. (A) Sample 
traces showing the average of five paired pulses at 25 ms intervals in slices from control (CNT) 
and STZ-induced diabetic mice in WT and RAGE-KO groups. (B) Graphs summarizing paired-
pulse ratio as the average amplitude of the second fEPSP divided by the average amplitude of the 
first fEPSP. Inset, shows a comparison of the paired-pulse ratio solely at the 25 ms interval, at 
which the significant difference was observed. In each hippocampal slice, facilitation was tested 
using pairs of stimuli at intervals ranging from 25 ms to 800 ms. Values expressed as the mean ± 
SEM from WT CNT (n=13 slices from 6 mice), WT STZ (n=15 slices from 7 mice), RAGE-
KO CNT (n=9 slices from 5 mice), and RAGE-KO STZ (n=10 slices from 5 mice). Means were 
statistically compared by two-way ANOVA at specific intervals followed by Sidak’s multiple 
comparison test; * p<0.05.  
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3.4.3 STZ-induced diabetes decreased the expression of the AMPA GluA1 subunit in the 
hippocampus of WT, but not RAGE KO, mice 
Since induction and maintenance of LTP requires AMPA and NMDA receptor function, we next 
concentrated on the expression levels of AMPA and NMDA receptor subunits in hippocampi of 
control and STZ-induced diabetic mice, from both WT and RAGE-KO genotypes. Western blot 
analysis showed a significant reduction in expression of the AMPA receptor GluA1 subunit in the 
hippocampal tissues from WT diabetic mice, but not from RAGE-KO mice (Figure 3.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
61 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. RAGE-dependent changes in AMPA receptor expression, but not NMDA 
receptors, in STZ-induced diabetic mice. Representative immunoblots showing levels of AMPA 
receptor subunits in the hippocampi of control (CNT) and STZ-induced diabetic mice in (A) WT 
and (B) RAGE-KO groups. Levels of NMDA receptor subunits in the hippocampi of control 
(CNT) and STZ-induced diabetic mice are shown in (C) for WT and (D) for RAGE-KO groups. 
Bar graphs show the mean ± SEM levels of each protein after normalization to tubulin expressed 
as a percentage of control (n=4 in each group). Means were statistically compared by the Mann-
Whitney U test; * p<0.05. Protein samples for Western blotting were obtained from the bilateral 
hippocampi of four mice.  
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3.4.4 STZ-induced diabetes activated the MAPK signaling pathway in diabetic WT, but not 
RAGE KO, mice  
To better understand the link between RAGE downstream signaling and reduced AMPA receptor 
function, we next investigated regulatory proteins in the MAPK pathway. Hippocampi from STZ-
induced diabetic mice had, as expected (Chandna et al 2015a and 2015b), a significant increase in 
RAGE and NF-κB expression, accompanied by no change in the α-secretase ADAM10, which 
cleaves membrane-bound RAGE to generate a secretory form (Raucci et al., 2008). The increase 
in NF-κB detected in WT mice was absent in hippocampi from RAGE-KO mice, which  lack 
functional RAGE expression (Figure 3.4) (Chandna et al., 2015a; Myint et al., 2006; Harashima 
et al., 2006).  
Next, we concentrated on the kinases downstream from RAGE, which are linked to NF-κB 
expression (Figure 3.5). We observed significant increases in total p38 and pp38, whereas there 
were no changes in total ERK1/2 and pERK1/2 in the hippocampi of WT STZ-induced diabetic 
mice. Levels of p38 and pp38 kinases, however, were unchanged in the hippocampi of RAGE KO 
STZ-induced diabetic mice (Figure 3.5 A-B).   
Lastly, we concentrated on the c-Jun N-terminal kinase (JNK), which is required for GluA1 
turnover at the plasma membrane (Myers et al., 2012). In hippocampal tissues from WT diabetic 
mice we observed an increase in total JNK accompanied by a decrease in pJNK. We also observed 
a decrease in pMEK7, which phosphorylates JNK (Tournier et al., 2001), and no change in its 
phosphatase, pMKP1/2. Consistent with a decrease in pJNK, we also observed a decrease in 
GluA1-pSer831 and GluA1-pSer845; these phosphorylated version of GluA1 are both required for 
surface expression of GluA1 subunits. None of these changes were observed in hippocampal 
tissues from RAGE-KO diabetic mice (Figure 3.5 C-D).  
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Figure 3.4.  STZ-induced diabetic mice in WT showed changes in the expression levels of 
RAGE and NF-κB. Representative immunoblots showing levels of RAGE and NF-κB in the 
hippocampi of control (CNT) and STZ-induced diabetic mice in (A) WT and (B) RAGE-KO 
groups. Bar graphs show the mean ± SEM levels of each protein after normalization to tubulin 
expressed as a percentage of control (n=4 in each group). Means were statistically compared by 
the Mann-Whitney U test; * p<0.05. Protein samples for Western blotting were obtained from the 
bilateral hippocampi of four mice.  
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Figure 3.5.   STZ-induced diabetic mice in WT showed changes in the phosphorylation state 
of the AMPA GluA1 subunit and regulatory proteins in the MAPK pathway downstream 
from RAGE. Representative immunoblots showing levels of phospho-Ser831 and phospho-
Ser845 GluA1, total p38 and pp38, total ERK1/2 and pERK1/2, total JKN and pJNK as well as 
JNK kinase pMEK and JNK phosphatase pMKP1/2 in the hippocampi of control (CNT) and STZ-
induced diabetic mice in (A and C) WT and (B and D) RAGE-KO groups. Bar graphs show the 
mean ± SEM levels of each protein after normalization to tubulin expressed as a percentage of 
control (n=4 in each group). Means were statistically compared by the Mann-Whitney U test; * 
p<0.05. Protein samples for Western blotting were obtained from the bilateral hippocampi of four 
mice.  
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3.4.5 High glucose decreased AMPA-mediated currents in hippocampal neurons from WT, 
but not from RAGE KO, mice 
To better understand the effect of hyperglycemia at the cellular level, we next examined the 
function of the glutamate receptors responsible for TBS-induced LTP. Thus, we study the effect 
of high glucose on AMPA and NMDA receptor function in the presence and absence of RAGE 
expression.  
Currents were evoked using AMPA (50 µM) or NMDA (50 µM) in voltage-clamp mode, at a 
holding potential of -60 mV, and were expressed as current densities. To better quantify the 
magnitude of fast-inactivating currents, we also calculated the ionic charge (area under the curve) 
carried by the evoked currents.  
In the WT cultures, high glucose caused a significant reduction in AMPA-evoked ionic charge, 
while NMDA-evoked ionic charge was unaffected (Figure 3.6 D-E). No significant changes were 
observed in AMPA- or NMDA-evoked current density or ionic charge in either the control or high-
glucose RAGE-KO cultures (Figure 3.6 A-F). These data are consistent with our observations of 
reduced expression and phosphorylation of AMPA GluA1 subunits and suggest that activation of 
the RAGE signaling pathway in high glucose modulates AMPA receptor function, but not NMDA, 
in hippocampal neurons.  
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Figure 3.6. Effect of high glucose on whole-cell currents evoked by AMPA and NMDA 
receptors in cultured hippocampal neurons. Representative example traces of AMPA (50 µM)- 
(A) and NMDA (50 µM)-evoked (D) currents in cultured hippocampal neurons from WT and 
RAGE-KO mice, maintained in either control (CNT) or high-glucose (HG) conditions. Bar graphs 
summarize (B) AMPA- and (E) NMDA-evoked current density (IAMPA or INMDA) and (C, F) ionic 
charge (Q x 104) values expressed as the mean ± SEM. Means were statistically compared by two-
way ANOVA, followed by Sidak’s multiple comparison test; * p<0.05. For AMPA experiments: 
WT CNT (n=11), WT HG (n=10), RAGE-KO CNT (n=12), and RAGE-KO HG (n=10). For 
NMDA experiments: WT CNT (n=16), WT HG (n=11), RAGE-KO CNT (n=10), and RAGE-KO 
HG (n=10).  
 
 
67 
 
3.4.6 High glucose caused a decrease in neuronal excitability in WT, but not in RAGE-KO, 
hippocampal neurons   
To explore whether high glucose affects the ability of hippocampal neurons to participate in 
synaptic transmission, we concentrated on parameters of cell excitability. We evoked action 
potentials in cultured hippocampal neurons from WT and RAGE-KO mice maintained in either 
control or high-glucose conditions. Action potentials were generated in current clamp mode by 
injecting a series of depolarizing current steps (0-900 pA, at 100-pA increments) for 500 ms. To 
mitigate the effects of differences in resting membrane potentials among cells, we held the cells at 
approximately -60 mV before applying the current step protocol. We observed a significant 
interaction between genotype and high glucose treatment in action potential counts at the 100 pA 
depolarizing current step, indicating that the effect of high glucose on neuronal excitability differed 
significantly between the two genotypes (Figure 3.7 A-B). The reduced excitability at the 100 pA 
step was not accompanied by changes in other parameters of action potentials, such as threshold 
voltage (Vth), peak amplitude (APampl), half-width (APhw), inter-spike interval (APisi), or after-
hyperpolarization amplitude (AHPampl) (Figure 3.7 C). Furthermore, no significant changes were 
observed in passive membrane properties between cultured neurons from either WT or RAGE-KO 
mice exposed to control and high-glucose conditions, including resting potential (Vm), membrane 
resistance (Rin), and membrane capacitance (Cm) (Table 3.2). 
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Figure 3.7. High glucose decreases cell excitability in cultured hippocampal neurons from 
WT mice. (A) Representative action potential traces from WT and RAGE-KO cultured 
hippocampal neurons (P0-P2) maintained in either control (CNT) or high-glucose (HG) 
conditions. Action potentials were generated by a series of depolarizing current steps at 100-pA 
increments for 500 ms. Example traces are from a 100-pA depolarizing current step. (B) Mean 
action potential counts (AP count) expressed as the mean ± SEM from WT CNT (n=17), WT HG 
(n=10), RAGE-KO CNT (n=11), and RAGE-KO HG (n=11). The inset, shows a comparison of 
the AP count solely at the 100-pA depolarizing current step. (C) Table summarizes the action 
potential parameters, such as threshold voltage (Vth), peak amplitude (APampl), half width 
(APhw), inter-spike interval (APisi), and after-hyperpolarization amplitude (AHPampl). Means 
were statistically compared by two-way ANOVA, followed by Sidak’s multiple comparison test. 
(I): significant interaction between HG treatment and the genotype (F(1, 45)=4.913, p<0.05).  
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Table 3.2. Passive membrane properties.  
 
Passive membrane properties of cultured hippocampal neurons from WT and RAGE-KO mice 
maintained in either control (CNT) or high-glucose (HG) conditions. Table summarizes cell 
capacitance (Cm), membrane resistance (Rm) and membrane potential (Vm) during whole-cell 
recordings. Means were statistically compared by two-way ANOVA, followed by Sidak’s multiple 
comparison test.  
 
 
 
 
 
 
 
 
 
 
 
 
Groups  Cm (pF)   Rm (MΩ) Vm (mV) 
WT CNT (n=23) 32.08 ± 2.19 406.27 ± 29.94 -53.98 ± 1.2 
WT HG (n=20)  30.23 ± 2.13 435.39 ± 36.87 -56.32 ± 2.88 
RAGE-KO CNT (n=18) 36.66 ± 2.67 501.43 ± 61.57  -52.79 ± 1.56  
RAGE-KO HG (n=19)  37.16 ± 3.58 481.38 ± 57.85  -54.02 ± 1.9 
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3.4.7 High glucose caused an increase in oxidative stress in WT, but not in RAGE-KO, 
hippocampal neurons  
To investigate whether the redox state of hippocampal neurons may contribute to hippocampal 
abnormalities during high glucose condition, as observed in other neurons (Vincent et al., 2005; 
Chandna et al., 2015a), we next monitored both cytosolic ROS levels and cell viability. For 
cytosolic ROS we used the ROS sensitive dye CM-H2DCFDA. We observed a significant main 
effect of high glucose treatment on cytosolic ROS levels as well as a significant difference between 
the two genotypes (Figure 3.8). There was also a significant interaction between high glucose 
treatment and the genotype, indicating that the effect of high glucose on cellular redox state 
differed significantly between the two genotypes. Consistent with this, we observed a significant 
increase in ROS levels in hippocampal neurons cultured from WT but not from RAGE-KO mice 
(Figure 3.8). The latter further supports the link between RAGE signaling and activation of the 
MAPK pathway that eventually leads to further expression of RAGE and decreased surface 
expression of the AMPA GluA1 subunit. 
Next, we evaluated cell viability in hippocampal cultures under control and high glucose 
conditions by annexin V and PI fluorescence (Lam et al., 2018). The evaluation of cell viability 
served two purposes: first, to confirm that contrary to the historical assumption that cultured 
neurons could not survive in normal glucose levels, our cells were healthy in 5 mM glucose and 
second, to evaluate whether the high glucose treatment had any impact on cell viability of 
hippocampal neurons, as it has been previously reported for hippocampal and peripheral neurons 
(Russell et al., 2002; Vincent et al., 2005; Kahya et al., 2016). We observed no significant 
difference in neuronal viability between control (5 mM glucose) and high glucose (25 mM 
glucose) conditions in either genotype (Figure 3.9). In contrast, hippocampal neurons exposed to 
1 mM H2O2 as a positive control showed a significant increase in the percent of cells positive for 
annexin V and PI (indicative of cell death). These data thus confirm the survival of primary 
hippocampal culture in control glucose levels (5 mM) and also the lack of significant cell loss 
under high glucose (25 mM) condition.  
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Figure 3.8. High glucose induces intracellular ROS accumulation in cultured hippocampal 
neurons from WT mice. (A) Representative images of ROS detection by CM-H2DCFDA 
fluorescence from WT and RAGE-KO cultured hippocampal neurons (P0-P2) in control (CNT), 
high-glucose (HG), and 100 µM H2O2 (as positive control). (B) Bar graphs summarize the mean ± 
SEM pixel intensity for neurons from WT CNT (n=140), WT HG (n=175), WT H2O2 (n=148), and 
RAGE-KO CNT (n=178), RAGE-KO HG (n=168), and RAGE-KO H2O2 (n=151) mice 
respectively. Means were statistically compared by two-way ANOVA followed by Sidak’s 
multiple comparison test; ** p<0.01; *** p<0.001. (T): significant main effect of HG treatment 
(F(1, 657) = 28.42, p<0.001); (G): significant genotype differences (F(1, 657)=115.6, p<0.001); (I): 
significant interaction between genotype and HG treatment (F(1, 657)=11.27, p<0.001). Scale bars 
represent 30 μm.   
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Figure 3.9. Percent of apoptotic/necrotic cells in primary cultured hippocampal neurons 
from WT and RAGE-KO groups. Representative images for annexinV-FITC and propidium 
iodide (PI), in control (CNT), high-glucose (HG), and 1mM H2O2 (as positive control) from (A) 
WT and (C) RAGE-KO cultured hippocampal neurons (P0-P2) (40x magnification). Yellow 
arrows show representative examples of an apoptotic/necrotic cell. Bar graphs summarize the 
percentage of annexinV- and PI-positive cells in CNT, HG, and 1 mM H2O2 from (B) WT and (D) 
RAGE-KO cultured hippocampal neurons respectively (n=4 dishes per condition). All data are 
represented as mean ± SEM. Means were statistically compared by two-way ANOVA followed 
by Sidak’s multiple comparison test; *** p<0.001. Significant effect of H2O2 treatment on 
annexin-V (F(2, 327)=906.3; p<0.001) and on PI (F(2, 327)=868.2, p<0.001) positive cells. Scale bars 
represent 50 μm. BF: Bright Field 
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3.5 Discussion  
This study provides novel evidence of RAGE-dependent hippocampal changes in high-glucose 
and diabetic conditions, which may contribute to the impairment of cognitive abilities in diabetic 
patients.  
 
3.5.1 LTP impairment in diabetes 
Type 1 and type 2 diabetes have both been associated with cognitive dysfunction (Kodl and 
Seaquist, 2008), which in animal models of diabetes are concomitant with biochemical and 
electrophysiological abnormalities in the CA1 region of the hippocampus, particularly with defects 
in LTP expression (Biessels et al., 1998; Lynch, 2004; Artola et al., 2005). Spatial learning and 
LTP expression in the CA1 region of the hippocampus were impaired in STZ-induced diabetic rats 
(Biessels et al., 1998; Artola et al., 2005).  
The alterations in LTP observed in diabetic animal models can stem from both pre- and 
postsynaptic components (Trudeau et al., 2004). Impaired glutamate release was reported in the 
cerebral cortex of STZ-induced hyperglycemic rats (Guyot et al., 2000) and changes in PPF, a 
form of presynaptic plasticity indicative of the probability of neurotransmitter release (Trudeau et 
al., 2004), was shown to correlate with hippocampal LTP induction (Kleschevnikov et al., 1997). 
In our study, RAGE expression was required for both LTP impairment and increased PPF, 
indicating the RAGE-associated changes taking place during STZ-induced diabetes (insulin 
deficiency and hyperglycemia) were pre- and post-synaptic. The increase in PPF suggest that 
RAGE expression was required for the reduction in presynaptic neurotransmitter release, which 
would contribute to LTP impairment.  
Statistical analysis of our LTP experiment also revealed a significant difference between the two 
genotypes. It has been previously reported that during CNS development RAGE is required for 
neurite outgrowth and neuronal differentiation (Wang et al., 2008), suggesting that RAGE-KO 
mice may have electrophysiological differences due to a developmental effect. Nevertheless, the 
STZ-induction of diabetes spared these mice from any further effect on LTP, indicating that RAGE 
expression is required for the induction of synaptic plasticity abnormalities in diabetic mice.  
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More importantly, we identified post-synaptic changes in AMPA receptors, which are essential for 
LTP induction (Isaac, 2003). These receptors, which are normally absent or electrophysiologically 
silent, are recruited to the membrane upon LTP induction. In diabetes, however, changes in 
receptor properties are shown as reduced [3H] AMPA binding in various brain structures, including 
the hippocampus, in STZ-induced diabetic rats (Chabot et al, 1997; Gagne  et al., 1997), and lower 
glutamate affinity for hippocampal AMPA receptors, supported by reduced GluA1 subunit 
immunoreactivity (Gagne et al., 1997). Furthermore, reductions in NMDA currents and NMDA 
receptor subunits (GluN1 and GluN2B) are reported in the hippocampus of STZ-induced diabetic 
animals (Gardoni et al., 2002; Nardin et al., 2016). However, GluN2A expression was increased 
in hippocampal synaptosomal fractions of non-obese diabetic (NOD) mice, which also showed 
impaired LTP expression in the CA1 region (Valastro et al., 2002).  
 
3.5.2 RAGE signaling in hippocampal neurons 
A strong association has been proposed between the activation of the AGE-RAGE pathway during 
diabetes and cognitive impairments characteristic of Alzheimer’s disease (AD) (Srikanth et al., 
2011). Treatment of hippocampal neurons or brain slices with AGEs decreases synaptic densities 
and impairs hippocampal LTP, effects that were largely RAGE-dependent (Zhang et al., 2014; 
Wang et al., 2018). How RAGE expression affects synaptic plasticity in diabetes, however, had 
not been studied until this work.  
A key consequence of RAGE signaling is the activation of transcription factors—particularly NF-
κB—and subsequent transcription of pro-inflammatory cytokines, RAGE up-regulation, and 
generation of more ROS (Granic et al., 2009). As in our model of STZ-induced insulin deficiency 
and hyperglycemia, it is reported that type 1 diabetes is linked to the increased 
expression/activation of NF-κB in the hippocampus (Patel et al., 2009).  
Activation of the RAGE-NF-κB pathway induces oxidative stress, which may be the link between 
diabetes and synaptic transmission deficits as it affects the expression and function of glutamate 
receptors (Klann et al., 2011). In STZ-induced diabetic mice, as the level of oxidative stress 
increased a decline in expression of the AMPA GluA2 subunit was observed in the hippocampus 
(Pandey et al., 2015). Our data do not show a significant decrease in GluA2 subunits, although a 
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decreased trend was observed in WT but not in RAGE-KO STZ-induced diabetic mice. However, 
we did observe a significant reduction in the expression of the AMPA GluA1 subunit in STZ-
induced diabetic mice that required RAGE expression, suggesting it may play a key role in synaptic 
alterations in diabetes. 
The phosphorylation of the AMPA GluA1 subunit at Ser845 is key for surface expression of 
AMPA upon NMDA activation during activity-dependent LTP (Oh et al., 2006; Derkach et al., 
2007). The latter is consistent with our findings showing reduced expression of the GluA1 subunit 
and pSer831 and pSer845 GluA1 in the hippocampi of WT STZ-induced diabetic mice, which 
correlates with the impaired LTP detected in these mice. Therefore, our findings may be the result 
of changes in subunit incorporation, phosphorylation state, and surface expression of AMPA 
receptors.   
In addition to effects on AMPA receptors, we observed a decrease in neuronal excitability in 
cultured hippocampal neurons exposed to high-glucose conditions only in the WT group. This is 
consistent with other findings of reduced excitability of hippocampal neurons in hyperglycemia 
(Chandna et al., 2015b), oxidative stress (Pardillo-Diaz et al., 2016), and aging (Oh et al., 2010). 
None of the action potential or membrane property parameters that we studied showed changes 
that could underlie the reduction in excitability. Therefore, further research on ion channels not 
directly involved in spike generation (e.g. voltage-gated Ca2+ channels) should be considered.  
 
3.5.3 MAPKs and modulation of synaptic transmission  
To better understand the relationship between RAGE signaling and changes in AMPA receptor 
expression/function in STZ-induced diabetes, we first concentrated on the mitogen-activated 
protein kinase (MAPK) family, which regulate synaptic plasticity and signaling glutamate receptor 
trafficking (Gu and Stornetta, 2007). In fact, inhibition of the MAPK cascade causes a strong 
attenuation during LTP induction in the hippocampus CA1 region (English and Sweatt, 1997). All 
three members of the MAPK family (ERK, p38 and JNK) are involved in modulation of synaptic 
plasticity (Thomas and Huganir, 2004).  
The MAPK cascade also regulates AMPA receptor trafficking in the hippocampus (Boudreau et 
al., 2007). ERK activation is suggested to mediate synaptic insertion of AMPA receptors during 
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LTP (Boudreau et al., 2007). Consistent with our findings, AMPA receptor insertion during LTP 
is associated with decreased p38 activity (Boudreau et al., 2007).  
The role of JNK in AMPA receptor trafficking is, however, more controversial. During LTP, 
NMDA-induced JNK signaling mediates removal of GluA1- and GluA2-containing AMPA 
receptors (Zhu et al., 2005). However, metabotropic glutamate receptor-induced activation of 
calcium/calmodulin-dependent protein kinase (pCaMK)/pJNK and/or PKA/pJNK is thought to 
increase phosphorylation of GluA1-Ser831 and Ser845 (Ahn and Choe, 2009) and subsequently 
an increase in its surface expression (Oh et al., 2006). The latter parallels our findings showing a 
reduction in pJNK together with reduced pSer845 of the GluA1 AMPA receptor subunit, which 
should reduce AMPA surface expression.   
Also comparable with our findings, a reduction in pJNK was reported in the hippocampus of STZ-
treated rats while the pERK/total ERK ratio was unaffected (Dalli et al., 2018). However, reports 
by others show that phosphorylation of ERK1/2 and p38 were higher in the hippocampus of STZ-
induced diabetic rats, while the level of pJNK was not changed (Jing et al., 2013). As in our study, 
pp38/total p38 ratio was higher in the hippocampus and cortex of STZ-induced rats (Liu et al., 
2016).  
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Hyperglycemia-induced oxidative stress is one of the important upstream mediators of MAPK 
activation (Purves et al., 2001). As in our study, oxidative stress activated p38 in sensory neurons 
after exposure to high glucose in vitro, after STZ treatment in vivo, and in the sural nerves of type 
1 and type 2 diabetic patients (Sharma et al., 2010). The increase in hyperglycemia-induced 
oxidative stress is indeed initiated/exacerbated by RAGE ligands, which phosphorylate and 
activate various protein kinases involving MAPKs and subsequently the NF-κB pathway (Zong et 
al., 2010).  
The contribution of p38 signaling to the activation of NF-κB occurs through the phosphorylation 
of the transcriptionally active subunit of the NF-κB complex (Olson et al., 2007). Interestingly, 
NF-κB was shown to negatively regulate JNK (Lin, 2003) through growth arrest and DNA 
damage-inducing protein β (GADD45β), by binding to, and inhibiting, the JNK kinase, mitogen-
activated protein kinase kinase 7 (MKK7 or MEK7) (Nakano, 2004). The latter supports our 
findings showing a decrease in JNK and MEK7 phosphorylation, along with an increase in NF-κB 
expression. 
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We also show a reduction in GluA1 subunit expression and phosphorylation, concomitant with 
reduced JNK phosphorylation and MEK7 expression, suggesting these mechanisms may 
contribute to hippocampal impairment in diabetes. The increase in phosphorylated and total p38 
protein level, on the other hand, may lead to the generation of pro-inflammatory responses by 
regulating NF-κB activity, which further amplifies oxidative stress and promotes RAGE up-
regulation—a cycle that can intensify diabetic complications and inflammation-induced tissue 
injury (Figure 3.10).   
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Figure 3.10. A schematic diagram showing the postulated mechanisms underlying the 
RAGE-dependent synaptic impairments in the hippocampus of diabetic mice. Activation of 
the RAGE pathways by its ligands (e.g. AGEs) in diabetes leads to oxidative stress, which in turn 
increases total JNK and p38 protein levels, as well as p38 phosphorylation. Increases in JNK and 
p38 result in increased activation of NF-κB, which further promotes RAGE up-regulation and 
amplifies oxidative stress. In addition, NF-κB negatively regulates JNK phosphorylation by 
inhibiting the JNK kinase, MEK7. Reduced JNK activity, due to reduced JNK phosphorylation, 
leads to decreased AMPA GluA1 subunit expression and phosphorylation and subsequent 
internalization of the receptor. These changes will result in decreased neuronal excitability and 
LTP impairment. Dashed lines indicate pathways that were downregulated/inactive in diabetic 
mice, and red arrows represent changes in protein detection by immunoblotting. 
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Although the main focus of this work was to investigate whether/how RAGE plays a role in some 
hippocampal complications of diabetes, it is important to note that the role and interplay of other 
possible factors also need to be taken into consideration in our model. Insulin, for example, is one 
of these factors. The interplay between hippocampal insulin receptors and RAGE would be worth 
investigating since MPAKs are shown to affect insulin receptors, and in turn, insulin therapy is 
found to affect the activity of MAPK signaling molecules (Iloun et al., 2018). Furthermore, insulin 
signaling is reported to affect glutamate receptor trafficking and synaptic plasticity in the 
hippocampus (Grillo et al., 2015). In our study, we generated a model of diabetes based on insulin 
deficiency and hyperglycemia, with levels of circulating insulin below the detectable range by 
ELISA. The fact that our insulin-deficient diabetic model was generated in both genotypes with 
similar insulin and glycemic parameters, allowed us to evaluate RAGE as a variable. However, 
considering that insulin can modulate synaptic transmission and plasticity in the hippocampus 
(Zhao et al., 2019), and that application of exogenous insulin (e.g. intraventricular and 
intraperitoneal) has provided some encouraging outcomes, particularly at the behavioral studies 
(Benedict et al., 2007; Shemesh et al., 2012), it becomes relevant to evaluate the effect of insulin 
on the RAGE-mediated deleterious effects of diabetes described here. The effects of exogenous 
insulin on hippocampal function and in the context of diabetes are contradictory (Maimaiti et al., 
2016; Bell and Fadool, 2017) and further research will be required to evaluate the contribution of 
RAGE in not only models of insulin deficiency (such as STZ-induction), but also in insulin 
resistance and exogenous insulin administration.  
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CHAPTER 4 
GENERAL DISCUSSION 
 
Diabetes is a most common metabolic disorder with long-lasting complications and abnormalities 
in various body functions and systems. Micro- and macrovascular complications, as well as 
vasculature-independent cellular complications of diabetes have been well investigated in clinical 
and experimental diabetes. RAGE is shown to play a part in most diabetic complications. However, 
there is still the need for further knowledge on the role and/or the mechanisms of RAGE signaling 
in CNS complications of diabetes, particularly on those that impact quality of life in diabetic 
patients, such as impairments in learning and memory and cognitive function. In this dissertation, 
I tried to answer the question of whether RAGE is involved in cognitive dysfunction in diabetes 
and what RAGE-dependent mechanisms could underlie these detrimental effects of the disease. 
 
4.1 Major findings   
We found that STZ-induced diabetes caused a significant reduction in locomotor activity and an 
increase in anxiety-like behaviour in both WT and RAGE-KO mice. Our findings also showed that 
although recognition memory was spared in STZ-induced diabetes in both genotypes, spatial 
memory was impaired in STZ-induced diabetic mice in WT but not in the RAGE-KO group. This 
impairment in hippocampal-dependent spatial memory was consistent with impairment in synaptic 
plasticity, as measure by LTP and PPF, in the hippocampus and correlated with reduced expression 
and phosphorylation of the GluA1 subunit of the AMPA receptor in WT STZ-induced diabetic 
mice. These changes were associated with the activation of the MAPK pathway, i.e. increased total 
p38, pp38, and NF-κB and decreased pJNK and its kinase, MEK7. Consistently, in hippocampal 
cultures, high glucose caused a RAGE-dependent reduction of AMPA-evoked currents, as well as 
cell excitability, and an increase in cytosolic ROS.   
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4.2 STZ-induced behavioural abnormalities  
Our findings show that STZ-induced diabetes causes a deficit in locomotor activity in both WT 
and RAGE-KO groups, shown as a significant reduction in distance traveled and movement time. 
This is consistent with previous reports indicating a decrease in locomotor activity in STZ-induced 
diabetic animals (Haider et al., 2013; Bădescu et al., 2016b; Bensaoula et al., 2016; Gao et al., 
2018). Such reduction in locomotor activity is suggested to be associated with deficits in motor 
function due to dysregulation of the cholinergic system (Sherin et al., 2012). In particular, 
significant downregulation of acetylcholine esterase (AChE) and choline acetyltransferase (ChAT) 
and changes in the expression and binding properties of muscarinic and nicotinic acetylcholine 
receptors in the striatum are reported in STZ-induced diabetic rats (Sherin et al., 2012). In addition, 
the cerebellum, a brain area also involved in the control and execution of motor functions, has 
shown several alterations such as increased cellular degeneration, increased activation and 
proliferation of astroglia and microglia, loss of glutamate transporters on the astrocytes and 
subsequent glutamate excitotoxicity in STZ-induced diabetic rats with impaired locomotor activity 
(Nagayach et al., 2014). The associative interplay between these factors in the cerebellum is 
suggested to result in motor function deficits following diabetes (Nagayach et al., 2014). In our 
study, however, we cannot conclude if decreased locomotor activity observed in STZ-induced 
diabetic mice is due to motor function deficits or due to other factors such as higher anxiety or 
other effects associated with the STZ treatment. 
We also observed a significant effect of the STZ treatment on decreased time spent in the center 
of the OF, which could be interpreted as an anxiety-like behaviour; however, we can not discard 
the possibility that it could be the result of lower locomotor activity. The results of the MWM test 
showing increased distance traveled and swimming velocity in STZ-induced diabetic mice, 
however, support an anxiety-like phenotype in this group as compared to age-matched controls. 
Increased anxiety-like behaviours have been previously reported in STZ-induced diabetic animals 
(Aksu et al. 2012; Gupta et al., 2014; Damian et al., 2014; Chu et al., 2017) and have been 
correlated with an increase in the HPA axis activity and glucocorticoid levels, lower levels of 
insulin and insulin-like growth factors (IGFs), reduced number of neurons, and changes in 
neurotransmitters, such as GABA and monoamines, in different regions of the brain such as 
prefrontal cortex (PFC), amygdala and the hippocampus in response to diabetes (Duarte et al., 
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2000; Gomez et al., 2003; Antony et al., 2010; Shpakov et al., 2011; Aksu et al. 2012; Torres et 
al., 2013 ; Gupta et al., 2014; Soto et al., 2019).  
The result of the NOR test, on the other hand, did not show any difference in the novel object 
recognition memory between STZ-induced diabetic mice and age-matched control in either 
genotype. This is inconsistent with previous reports that indicated impairments in novel object 
recognition memory, shown as a significant reduction in the discrimination index, following STZ-
induced diabetes (King et al., 2013; Jabbarpour et a., 2014; Patel et al., 2016). Such discrepancy 
might be due to longer duration of STZ treatment (from eight to ten weeks) in the above-mentioned 
studies as compared to the present study (King et al., 2013; Jabbarpour et a., 2014; Patel et al., 
2016). In this regard, the duration of diabetes is shown to have an impact on the severity of diabetic 
complications such as cognitive functions (Zilliox et al., 2016).  
The rodent hippocampus is suggested to play a role in object recognition memory, although other 
brain regions, such as perirhinal cortex, are also reported to play important roles (Brown and 
Aggleton 2001). Hippocampal glutamate efflux and mean firing rate of CA1 neurons showed 
increases during NOR test session (Cohen et al., 2013), consistent with other reports that showed 
novelty-induced increases in hippocampal activity (Rutishauser et al., 2008; Cohen et al., 2013), 
suggesting a role for the hippocampus in recognition memory. On the other hand, reports are 
controversial regarding the effect of hippocampal damage on the NOR test. While some studies 
report that hippocampal lesions as small as 1% can affect the novel object recognition memory 
(Cohen et al., 2013), others show spared recognition memory following hippocampal damage 
(Winters et al. 2004; Forwood et al. 2005; Mumby et al. 2005), even after lesions that encompassed 
about 75 to 100% of hippocampal volume (Broadbent et al., 2004), suggesting lack of hippocampal 
involvement in NOR memory.  
We did not conduct any experiments to investigate changes in hippocampal structural integrity, 
such as hippocampal volume and neuronal loss, and we cannot therefore come into any conclusion 
as to why recognition memory is spared in our STZ-induced diabetic mice. However, hippocampal 
damage by STZ-induced diabetes, reported previously (Pamidi et al., 2012), without any impact 
on the novel object recognition memory in our STZ-induced diabetic mice can suggest minimal or 
lack of hippocampal involvement in the task and/or larger involvement of other brain regions, such 
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as perirhinal regions, or the possibility of compensatory mechanisms by other structures within the 
medial temporal lobe (MTL) (Cohen et al., 2013), as discussed previously (Chapter 2).  
In addition, there is no published evidence, to our knowledge, on the role of RAGE in recognition 
memory under normal or pathological conditions. However, since our findings show a similar 
trend in discrimination index in both WT and RAGE-KO groups, we can infer that recognition 
memory is independent of RAGE expression and/or signaling, at least during the period our 
experiments lasted.  
Similarly, since our data shows a comparable trend in the parameters associated with locomotor 
activity in both WT and RAGE-KO groups, as reported previously (Sakatani et al., 2009), we can 
indicate that these parameters are also independent of RAGE expression and/or signaling. Anxiety-
like behaviour, however, seems to be dependent on RAGE expression since there was a significant 
genotype difference between RAGE-KO and WT mice in the time spent in the center of the OF 
test.  
Our hippocampal dependent-spatial memory tests, on the other hand, showed impairment in spatial 
memory in BM and MWM tasks in WT STZ-induced diabetic mice. This is consistent with other 
studies that show impairment in hippocampal-dependent spatial tasks such as MWM and BM in 
STZ-induced animal models of diabetes (Baydas et al., 2003b; Stranahan et al., 2008;  Jolivalt et 
al., 2010; Babri et al., 2013; Enhamre-Brolin et al., 2013; King et al., 2013; Anderson et al., 2014; 
Ghasemi et al., 2016; Tender and Razdan 2017).  
In the RAGE-KO group, however, there was no significant difference between STZ-induced 
diabetic group and the control in terms of spatial memory function, confirming that the effect of 
STZ on spatial memory differed significantly between the two genotypes.   
Hippocampal-dependent cognitive impairments elicited by diabetes are suggested to be associated 
with morphological changes in pyramidal neurons (Magarinos and McEwen, 2000), decreased 
hippocampal neurogenesis (Stranahan et al., 2008), alteration in neurotransmitter synthesis or 
release (Trudeau et al., 2004), and electrophysiological dysfunction in the hippocampus, 
particularly defects in the expression of LTP (Biessels et al., 2002), as well as changes in the 
expression and function of glutamate receptors (Gispen and Biessels 2000; Trudeau et al., 2004). 
However, whether and if so how RAGE plays a role in these effects has not been investigated. 
Therefore, in order to better understand the mechanisms associated with hippocampal-dependent 
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spatial memory impairment observed in our WT STZ-induced diabetic mice and the role of RAGE 
in this effect, we evaluated LTP, as a robust measure of synaptic plasticity that underlies 
mechanisms associated with memory (Nabavi et al., 2014).  
 
4.3 STZ-induced impairment in synaptic plasticity  
The results of our hippocampal slice electrophysiology showed an impairment in LTP along with 
an increased PPF ratio in STZ-induced diabetic WT mice. Our data is consistent with a wide range 
of literature that shows impairment in LTP in animal models of diabetes (Izumi et al., 2003; 
Trudeau et al., 2004; Artola et al., 2005; Kamal et al., 2005; Stranahan et al., 2008; Reisi et al., 
2010; Sasaki-Hamada et al., 2012).  
As mentioned in Chapter 3, pre- and postsynaptic components can contribute to hippocampal LTP 
impairment during diabetes (Blundon and Zakharenko 2008; Costa et al., 2017). In the presynapse, 
alterations in the synthesis and release of neurotransmitters could underlie changes in LTP 
(Trudeau et al., 2004; Lovinger, 2010). In order to study and quantify these changes, PPF is 
considered a useful electrophysiological tool for detection of presynaptic changes, such as 
probability of neurotransmitter release, for example, increased PPF is indicative of decreased 
probability of neurotransmitter release and vice versa (Schulz et al., 1994 and 1997; Trudeau et 
al., 2004). In the case of a decreased probability of neurotransmitter release, there will be a small 
postsynaptic response during the first pulse, but the build-up of calcium in the presynaptic terminal 
will cause a higher probability of release on the second pulse, and thus, a higher PPF. In contrast, 
in the case of an increased probability of neurotransmitter release, available transmitters will be 
depleted during the first pulse, and therefore there will be less transmitter to be released during the 
second pulse, leading to a lower PPF (Volgushev et al., 1997). Thus, the increased PPF and 
impaired LTP observed in our study might be due, at least in part, to reduction in neurotransmitter 
release from the presynapse. The latter has indeed been reported in some brain regions in diabetic 
rodents, such as impaired glutamate transportation and release in response to STZ-induced 
hyperglycemia in the cerebellum and cerebral cortex of rats (Guyot et al, 2000; Trudeau et al., 
2004; Nagayach et al., 2014).  
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On the other hand, lack of impairment in hippocampal LTP in our RAGE-KO model can be 
attributed, at least in part, to lack of changes in pre- and post-synaptic components, i.e. no changes 
in PPF nor in AMPA GluA1 subunit expression, phosphorylation, and function.   
Inconsistent with our data from hippocampal slices that suggest a decreased probability of 
neurotransmitter release, our cultured hippocampal neurons exposed to high glucose condition 
showed an increased frequency of mEPSCs (Appendix 1, Figure A.2), which could suggest an 
increased probability of presynaptic transmitter release (Ju et al., 2016). This discrepancy can be 
attributed, at least in part, to the limitations of the culture conditions, especially since our cultured 
hippocampal neurons form de novo synapses that, although glutamatergic, may not mimic the 
properties of actual hippocampal CA3-CA1 synapses.  
In the postsynapse, the impairment in LTP can be linked to the posttranslational modification of 
glutamate receptors (Trudeau et al., 2004). The latter is consistent with our finding showing that 
in the hippocampus of diabetic mice there was a reduction in expression and phosphorylation (Ser-
831 and 845) of the GluA1 subunit of AMPA receptors. Indeed, phosphorylation of GluA1 on Ser-
831 by CaMKII and on Ser-845 by PKA are important modifications that potentiate channel 
conductance and increase its open probability, respectively (Banke et al., 2000; Derkach, 2003). 
Furthermore, phosphorylation on Ser-845 increases GluA1 delivery to the plasma membrane 
modulating AMPA receptor surface expression during LTP (Ehlers, 2000; Oh et al, 2006), a 
mechanisms known to be triggered by NMDA receptor activation (Derkach et al, 2007). Thus, the 
significant decrease in the expression and phosphorylation of GluA1 subunit of AMPA receptor 
in our WT STZ-induced diabetic mice could explain the impairment observed in LTP due to 
changes in receptor function and trafficking, and therefore, in synaptic strength and plasticity 
(Chater and Goda, 2014).  
It also needs to be mentioned that, consistent with our data from hippocampal tissues, we observed 
a decreased expression of GluA1 subunit of AMPA receptor (although not quite significant) in 
cultured hippocampal neurons exposed to high glucose condition in cells from WT mice 
(Appendix 1, Figure A.3). We also detected a reduction in the expression of GluN1 subunit of 
NMDA receptor in both WT and RAGE-KO hippocampal cultures exposed to high glucose 
condition (Appendix 1, Figure A.3). This reduction in GluN1 subunit of NMDA receptor was not 
accompanied by electrophysiological changes in NMDA receptor-evoked currents and/or ionic 
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charge (Chapter 3). In addition, hippocampal tissues showed no significant differences in the 
expression of NMDA receptor subunits in either WT or RAGE-KO STZ-induced diabetic mice 
(Chapter 3).   
These discrepancies between cultured pyramidal neurons and actual hippocampal tissues, again, 
point to the limitations of culture conditions and highlight the need to validate results in actual 
tissues.  
Similarly, the literature on the effect of diabetes on NMDA receptors is controversial. For example, 
an increase in the GluN2A subunit level in crude hippocampal synaptosomal fractions (Valastro 
et al, 2002) and a significant increase in expression of hippocampal GluN1, GluN2A and GluN2B 
subunits (Wang et al., 2019) are reported in STZ-induced diabetic rodents. Some reports, on the 
other hand, indicate reductions in NMDA receptor expression and function. For instance, STZ-
induced diabetic rats showed a significant reduction in hippocampal content of the GluN1 subunit 
(Nardin et al, 2016), which indicates a reduction in the number of functional NMDA receptors 
(Salussolia et al., 2011). In addition, intracellular recordings from hippocampal slices of STZ-
induced diabetic rats showed reduced NMDA-evoked currents in pyramidal neurons together with 
a significant decrease in GluN2B subunit immunoreactivity (Gardoni et al, 2002). In contrast, 
NMDA-mediated component of excitatory postsynaptic potentials was unaffected after STZ 
treatment, suggesting that NMDA receptor function remained intact in STZ-induced diabetes 
(Chabot et al, 1997).  
Although research on the effect of diabetes on glutamate receptors expression and function is still 
ongoing and reports are controversial, factors such as duration of diabetes, age of animals at the 
onset of diabetes induction, and differences in the high glucose/diabetic models seem to play a role 
in such discrepancies.  
Although our results in cultured hippocampal neurons exposed to high glucose condition are not 
in accordance with those of STZ-induced diabetic mice in terms of the NMDA receptor expression, 
we did observe the same effect of high glucose in cultured neurons or STZ-induced diabetes in 
both genotypes. In cultured hippocampal neurons NMDA receptor expression showed reduction 
in GluN1 subunit expression in both WT and RAGE-KO groups exposed to high glucose, while 
in hippocampal tissues there was no significant differences in NMDA subunits expression in either 
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WT or RAGE-KO STZ-induced diabetic mice. These results underscore the possibility that 
NMDA receptor expression and function is independent of RAGE expression and/or signaling.  
 
4.4 STZ-induced RAGE-mediated effects  
As discussed above, impaired hippocampal-dependent spatial memory, reduced LTP and increased 
PPF, and changes in AMPA receptor expression, phosphorylation and function were observed in 
STZ-induced diabetes or high glucose condition in WT but not in RAGE-KO mice. In addition, 
significant increase in RAGE expression was detected in the hippocampi of WT STZ-induced 
diabetic mice. These findings suggest a contribution of RAGE in mediating the STZ-induced 
abnormalities observed in our study.  
One of the most likely signaling pathway candidates linking RAGE with synaptic impairment and 
cognitive dysfunction is the MAPKs pathway (Gu and Stornetta, 2007). As mentioned in Chapter 
1, MAPKs (ERK, p38 and JNK) are not only part of a well-known downstream signaling pathway 
from RAGE (Yeh et al., 2001), but are also abundantly expressed in the synapses (Gu and 
Stornetta, 2007) where they regulate synaptic function and glutamate receptor trafficking (Gu and 
Stornetta, 2007).  
Our findings show that although ERK and pERK levels were unaffected, total p38, pp38 and total 
JNK were increased and pJNK and its kinase, MEK7, were decreased in STZ-induced diabetic 
mice that had synaptic deficit and memory dysfunction.  
Consistent with this, phosphorylation of JNK was significantly decreased in the hippocampus of 
STZ-induced diabetic rats while the pERK/total ERK ratio was unaffected (Dalli et al., 2018). In 
another study, however, phosphorylation levels of ERK and p38 were higher in the hippocampus 
of diabetic rats, while the level of pJNK was not changed (Jing et al., 2013). Pp38/total p38 ratio 
was also significantly higher in the hippocampus of STZ-induced diabetic rats (Liu et al., 2016).  
Hyperglycemia-induced oxidative stress, initiated and/or exacerbated by RAGE-ligands binding, 
is one of the important upstream mediators of MAPKs activation (Purves et al., 2001; Price et al., 
2004; Sharma et al., 2010) and is shown to phosphorylate and activate various MAPKs that 
subsequently activate NF-κB (Yeh et al., 2001; Hermani et al., 2006; Wang et al., 2008; Zong et 
al., 2010). For example, phosphorylation of p38 MAPK and the activation of NF-κB were 
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significantly up-regulated when macrophages were cultured with lipopolysaccharide (LPS) and 
HMGB1, two RAGE ligands (Qin et al., 2009). Similarly, Aβ-induced RAGE involvement led to 
the activation of ERK and JNK, and subsequently NF-κB (Origlia et al., 2009; Pan et al., 2013).  
On the other hand, NF-κB negatively regulates the activation of the JNK pathway (Lin 2003) 
through GADD45β which binds to, and inhibits, the JNK kinase MEK7 (Nakano 2004). Reduced 
JNK phosphorylation/activity can have an impact on AMPA receptor trafficking as reported 
previously and controversially (Zhu et al., 2005; Ahn and Choe, 2009). The NMDA-induced JNK 
signaling pathway, for example, mediated removal of GluA1-and GluA2L-containing AMPA 
receptors during LTP (Zhu et al., 2005), while mGluRs-induced activation of PKA/pJNK pathways 
increased phosphorylation of GluA1-Ser831 and Ser845 (Ahn and Choe, 2009), and subsequent 
increase in AMPA receptor surface expression (Oh et al., 2006). This is in congruent with our 
results that showed reduced pJNK in line with reduced phosphorylation of GluA1-Ser831 and 
Ser845.   
Therefore, our findings showing an increase in cytosolic ROS production in cultured hippocampal 
neurons exposed to high glucose condition, and an increase in NF-κB levels along with significant 
decreases in pJNK, pMEK7 and GluA1-Ser831 and Ser845 phosphorylation in the hippocampi of 
WT STZ-induced diabetic mice are consistent with the reports in this field and can highlight the 
role of RAGE in mediating these effects, as none were observed in the RAGE-KO group.  
It needs to be noted that there was a significant genotype difference in cytosolic ROS levels 
detected by CM-H2DCFDA between WT and RAGE-KO hippocampal cultured neurons. 
Although in our study we did not explore the possible source of this difference, there are two main 
considerations that may be contributing to this effect. First, and as explained earlier in this thesis, 
is the physiological effect of RAGE during early stages of CNS development (Wang et al., 2008), 
although it is unclear how this could have an impact on basal redox state of culture hippocampal 
neurons. Second, a different level of cytosolic ROS between WT and RAGE-KO groups could 
indicate that RAGE, which is normally expressed in neurons at lower basal levels, is required to 
maintain basal redox state in neurons, and that lack of RAGE signaling may dysregulate signaling 
pathways involved in redox homeostasis. Indeed, differences in basal cytosolic ROS levels 
between WT and RAGE-KO mice have been previously reported in peripheral neurons, supporting 
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the idea that RAGE may play a physiological role in contributing to neuronal homeostasis 
(Chandna et al., 2015a).  
In addition, CM-H2DCFDA detects all individual hydrogen peroxide, superoxide anions, and the 
hydroxyl radicals, and the exact ROS profile cannot therefore be defined and distinguished. Some 
ROS species such as hydroxyl radicals have more deleterious effects (Yun et al., 2009) as 
compared to others such as superoxide anions, which play important roles in synaptic plasticity 
and memory by acting as a modulator of two kinases, CaMKII and PKA, which are involved in 
synaptic transmission (Hongpaisan et al., 2003 and 2004).  
In addition to increased ROS, our study also showed reduced cell excitability in cultured 
hippocampal neurons exposed to high glucose condition in the WT group. Interestingly, MAPKs 
signaling pathway plays a role in neuronal excitability as well (Chen et al., 2017). P38 MAPK 
inhibition, for example, increased hippocampal pyramidal neuron excitability (Poolos et al., 
2006; Jung et al., 2010), while inhibition of JNK had the opposite effect (Tai et al., 2017). 
Activation of p38 phosphorylates the voltage-gated sodium channel Nav1.6, which decreases its 
function (Wittmack et al., 2005), and impairs action potential generation in CA1 pyramidal 
neurons (Royeck et al., 2008). This is consistent with our findings that show a reduction in 
hippocampal neuronal excitability along with an increase in p38 phosphorylation/activity and 
reduced pJNK under high glucose/diabetic conditions, and further supports the role of RAGE in 
mediating impairment in hippocampal function.   
 
4.5 Challenges  
4.5.1 Effect of genotype  
As this was the first work, to our knowledge, that investigated the role of RAGE in diabetes-
induced hippocampal dysfunction, such as deficits in synaptic plasticity and cognitive impairment, 
there were not many studies available to compare and interpret our findings.  
During the analysis of some of our data we encountered the effect of genotype at the animal and 
cellular levels, which indicate that in addition to the pathological roles played by RAGE in the 
CNS during diabetes, there are some effects that need to be further considered when modeling 
diabetes in RAGE-KO mice. As discussed previously, RAGE expression is required for neuronal 
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differentiation during CNS development (Wang et al., 2008). However, how this could explain the 
differences we observed between the two genotypes is rather complex. The fact that cytosolic ROS 
levels were elevated in RAGE-KO neurons respect to WT may imply that overlapping signals are 
recruiting similar pathway(s), which may interfere with the effects of diabetes. Therefore, our 
findings on the effect of genotype may point at the difficulty of targeting RAGE and its signaling 
pathway for the treatment of diabetes.  
 
 
4.5.2 STZ-induced diabetic model  
Another limitation is related to the drawbacks of chemically-induced diabetes, i.e. by STZ due to 
its potential toxicity to other organs. Administration of STZ has been associated with hyperalgesia, 
hepatotoxicity and nephrotoxicity as well as changes in the lungs, intestines and testes, of which 
some are not reversible with insulin treatment (Palm et al., 2004; Graham et al., 2011; Gvazava et 
al. 2018). Although peripherally administered STZ does not cross the BBB and, therefore, cannot 
affect the brain directly (Šerbedžija and Ishii, 2012), peripheral side effects of STZ on animal’s 
well-being should not be overlooked. However, since our insulin deficient diabetic model was 
generated in both genotypes with similar insulin and glycemic parameters, RAGE can still be 
evaluated as a variable in our study.  
 
4.5.3 Cell cultures exposed to high glucose  
Although the cell cultures in our experimental groups were exposed to high glucose (25 mM) for 
a period of 1-2 weeks to mimic the chronic nature of diabetes, it needs to be noted that the glucose 
level usually increases gradually during the course of the disease in actual hyperglycemic state 
while our cultured hippocampal neurons were exposed to high glucose on the first day of culture. 
This points to another limitation of our cell culture model and emphasises the need to validate the 
results in actual hyperglycemic states in whole-animal models of diabetes, including 
pharmacologically induced and genetic models.   
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4.6 Future directions  
Now that we have suggested a working model, the following experiments can be taken into 
consideration for future directions in this field.     
1. The interplay between hippocampal insulin receptors and RAGE would be worth investigating 
since MPAKs are shown to affect insulin receptors, and in turn, inulin therapy is found to affect 
the activity of MAPK signaling molecules (Iloun et al., 2018). In addition, insulin signaling is 
reported to affect glutamate receptor trafficking and synaptic plasticity in the hippocampus (Grillo 
et al., 2015).   
Hippocampal insulin receptor expression and/or function can be evaluated in both WT and RAGE-
KO model in order to elucidate the role of the insulin receptor in some of the effects observed. 
Alternatively, the effect of insulin therapy can be evaluated in STZ-induced diabetic mice.  
2. Glucocorticoid receptors (GCRs) are another strong candidate to be considered since they are 
not only abundantly expressed in the hippocampus and show significant upregulation under 
diabetes, but also affect synaptic plasticity and cognitive function (Stranahan et al., 2008). 
Although there is no data available regarding the interaction between RAGE and GCRs, blockade 
of GCRs was shown to improve synaptic plasticity and cognitive function under diabetes 
(Stranahan et al., 2008), similar to what we observed in STZ-induced diabetic mice in the RAGE-
KO group. However, whether GCRs cause their negative effects independently or through 
interaction with other receptors such as RAGE needs further investigation.  
3. Since our model suggests an important role of pp38 in activating the NF-κB and subsequent 
effects on MEK7 and pJNK, taking advantage of the knock-in p38AF mouse model, which harbours 
dominant-negative mutations of the activating phosphorylation sites of the p38, could help better 
elucidate the role of this MAPK signaling molecule in the effects observed under diabetes.  
4. In addition to NF-κB, the role of other transcription factors such as cAMP-response element 
binding protein (CREB) can be evaluated as well, since CREB is also regulated by MAPKs and is 
involved in hippocampal synaptic plasticity and cognitive function (Benito and Barco 2010; 
Kandel 2012). 
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5. Looking further into other diabetes-induced hippocampal alterations such as hippocampal 
volume, neuronal density, morphological changes in pyramidal neurons, changes in glutamate 
synthesis and release and astroglial alterations, specially in STZ-treated RAGE-KO mice, could 
be of high importance as the role of RAGE has never been investigated in such diabetes-induced 
alterations.  
6. Since we propose RAGE-induced oxidative stress as an important upstream mediator of the 
MAPK signaling pathway and the negative effects of MAPKs in this correlational model, it would 
be worthwhile to investigate the effect of antioxidant treatment on MAPKs activation and AMPA 
receptor expression and function.  
In addition, looking further into the baseline differences in ROS level between WT and RAGE-
KO hippocampal neurons, such as identifying the profile of oxidative stress and distinguishing 
between the different species of free radicals, would be beneficial in better understanding the role 
of oxidative stress in the effects observed.     
7. Since the duration of diabetes and the age at the onset of diabetes play important roles in diabetic 
complications in animal models (Chen et al., 2005; Rajashree et al., 2011; Sasaki-Hamada et al., 
2012), it would be valuable to test the proposed model after different durations of diabetes and 
different ages at the onset of STZ treatment.  
8. The effects of RAGE knockout on CNS complications in type 2 diabetes would also be worth 
investigating, especially regarding the fact that type 2 diabetes is close to 90-95% of diabetic cases 
worldwide and that it is accompanied by reduced performance on multiple domains of cognitive 
function (Moheet et al., 2015).  
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4.7 Conclusion  
Although the role of RAGE has been well investigated in peripheral complications of diabetes, 
much less is known about the contribution of RAGE to CNS complications of the disease. This 
work is the first, to our knowledge, that shows the role of RAGE in hippocampal synaptic deficit 
and spatial memory impairment under diabetes.  
We postulate that RAGE-mediated oxidative stress under high glucose/diabetic condition induces 
increased phosphorylation and total p38 protein level as well as total JNK level, which result in 
increased activation of NF-κB and subsequent RAGE up-regulation and amplified oxidative stress.  
Activated NF-κB negatively regulates JNK phosphorylation by inhibiting the JNK kinase, MEK7. 
Reduced JNK activity due to reduced phosphorylation then leads to decreased AMPA GluA1 
subunit expression and phosphorylation and subsequent internalization of the receptor. These 
changes will result in decreased neuronal excitability, synaptic impairments and spatial memory 
deficit observed in this study.  
Although the main focus of this work was to investigate whether/how RAGE plays a role in 
hippocampal complications of diabetes, it is important to note that the role and interplay of other 
possible factors also need to be taken into consideration in this model for future investigations, as 
explained in the previous section. However, we hope that this primary model can provoke further 
understanding of CNS complications of diabetes and can serve as a start for developing new 
research in this area.  
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Role of RAGE signaling on hippocampal mEPSCs in cultured neurons exposed to 
high glucose condition 
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A.1 Introduction   
Diabetes, a very common metabolic disorder characterized by hyperglycemia, has long been 
associated with pathological complications in the peripheral and central nervous system (American 
Diabetes Association 2010). Deficits in hippocampal-dependent cognitive functions such as 
learning and memory impairments, which can originate from defects in hippocampal synaptic 
plasticity has been widely reported in diabetes (Kodl and Seaquist 2008; Wrighten et al., 2009; 
Rostami et al., 2013, Moheet et al., 2015; Saedi et al., 2016). On the other hand, NMDA and 
AMPA subtypes of glutamate receptors, as the major excitatory receptors within the central 
nervous system, have been shown to play important roles in synaptic transmission during learning 
and memory processes (Trudeau et al., 2004). Findings in the diabetic hippocampus describe 
changes in AMPA and NMDA receptors which may underlie impaired synaptic plasticity found 
in diabetic models (Trudeau et al., 2004; Sasaki-Hamada et al., 2012). RAGE, on the other hand, 
has been identified to be actively involved in vascular and nervous system pathologies of diabetes 
(Ramasamy et al., 2005; Yamaguchi et al., 2009; Chen et al., 2012; Kanasaki et al., 2013; 
Manigrasso et al., 2014). However, if RAGE plays a role in mediating diabetes-induced changes 
in glutamate receptor expression and function has not been explored yet. Therefore, we 
hypothesize that RAGE expression/signaling under high glucose condition changes the expression 
and function of AMPA and NMDA subtypes of glutamate receptors. 
Our findings show an increase in RAGE and a decrease in the expression of GluA1 subunit of 
AMPA receptor in cultured hippocampal neurons exposed to high glucose conditions in cells from 
WT mice, and a decrease in GluN1 subunit expression of NMDA receptor in both WT and RAGE-
KO hippocampal cultures exposed to high glucose condition. In addition, the frequency of 
mEPSCs showed a significant increase in cultured hippocampal neurons exposed to high glucose 
condition from both WT and RAGE-KO mice.   
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A.2 Materials and Methods  
A.2.1 Electrophysiological Recordings  
A.2.1.1 Miniature Excitatory Postsynaptic Currents (mEPSCs) 
Cultured hippocampal neurons maintained for 1–2 weeks in control and high glucose conditions 
were used for whole-cell patch-clamp recording. An Axopatch 200B amplifier (Molecular 
Devices, Palo Alto, CA) equipped with a 1 GΩ cooled head-stage feedback resistor and a Digidata 
1400A analog-to-digital converter (Molecular Devices) were used for voltage clamp protocol, and 
pClamp 10 (Molecular Devices) and Origin 9.0 software (OriginLab Corporation, Northampton, 
MA, USA) were used for data acquisition and analysis. Patch pipettes were made using thin-wall 
borosilicate glass capillaries (World Precision Instruments, FL, USA) using a vertical puller (PC 
10; Narishige Scientific Instrument Lab., Tokyo, Japan) and polished with a microforge 
(Narishige) to a final resistance of 3–8 MΩ when filled with intracellular recording solution. 
Recording electrodes were filled with the following intracellular solution (in mM): 65 KF, 55 KAc, 
5 NaCl, 0.2 CaCl2, 1 MgCl2, 10 EGTA, 2 MgATP and 10 HEPES, and pH was adjusted to 7.2 
with KOH (all from Sigma-Aldrich). Cultured neurons were perfused continuously at 1 ml/min 
with control perfusion solution consisting of (in mM): 140 NaCl, 5.4 KCl, 25 HEPES, 5 glucose, 
and 5 μg/ml phenol red; pH was adjusted to 7.4 with NaOH (all from Sigma-Aldrich); mEPSCs 
recordings were made in voltage clamp mode (Vm = −60 mV) using the whole-cell patch clamp 
technique. All the recordings were done in the presence of glycine (to enhance NMDAR opening), 
tetrodotoxin (to block Na+-dependent action potentials), bicuculline (to block GABA receptors), 
and strychnine (to block glycine receptors). In order to distinguish the AMPA and NMDA 
receptor-mediated components of mEPSCs, 2-amino-5-phosphonovaleric acid (AP-5, 50 μm) was 
used to block the NMDA receptors.  
 
A.2.2 Western blotting. For western blotting, whole cell extracts of hippocampal cultures 
maintained for 1-2 weeks in control and high glucose conditions were prepared using a 1% NP-40 
lysis buffer containing protease inhibitor cocktail. At least three replicas were used per condition 
(control or high glucose), for both WT and RAGE-KO mice. Each replica was generated from 5 
pups. Equal amounts of protein were loaded for each group and separated on 12% SDS 
polyacrylamide gels and electrotransferred onto a nitrocellulose membrane (Bio-Rad Laboratories, 
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Hercules, CA, USA). The membrane was then incubated with the following primary antibodies 
overnight at 4°C: rabbit anti-GluN1, anti-GluN2A, anti-GluN2B, anti-GluN2C, anti-GluN2D, 
anti-GluN3A and anti-GluN3B antibodies (1:1000, NMDA Receptor Antibody Explorer Kit, 
Alomone Labs), rabbit anti-GluA1, anti-GluA2, anti-GluA3 and anti-GluA4 antibodies (1:1000, 
AMPA Receptor Antibody Explorer Kit, Alomone Labs), rabbit anti-RAGE (1:1000; Abcam), 
rabbit anti-NF-kB p65 (1:1000, Abcam), rabbit anti-ADAM 10 (1:1000, Abcam) and mouse anti-
α-tubulin (1:2000; Sigma) antibodies followed by horseradish peroxidase-conjugated goat anti-
rabbit or goat anti-mouse secondary antibodies (1:20000; Bio-Rad Laboratories). Protein signals 
were visualized using enhanced chemiluminescence reagents (Bio-Rad) and quantified by 
densitometry using ImageJ software (NIH, Bethesda, MD, USA).  
 
A.2.3 Statistical Analysis. All values are reported as mean ± SEM and the significance threshold 
was set at 0.05 for all statistical tests performed. We used parametric t-test or non-parametric 
Mann-Whitney U test to compare two means, and two-way ANOVA to compare multiple means. 
All statistical analyses were carried out with GraphPad InStat 3.0 and Prism 8.0 (GraphPad 
Software Inc., La Jolla, CA, USA).  
This work was approved by the University of Saskatchewan’s Animal Research Ethics Board 
(Campanucci: protocol 20090082) and adhered to the Canadian Council on Animal Care 
guidelines for humane animal use.  
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A.3 Results  
 
A.3.1 High glucose increased the frequency of mEPSC in both WT and RAGE-KO neurons  
To study synaptic glutamate receptors (AMPA and NMDA) formed in vitro, we recorded 
spontaneous mEPSCs from cultured hippocampal neurons from neonatal WT and RAGE-KO mice 
(P0-P2).  
Our data showed no significant difference in the amplitude (Figure A.1 B), ionic charge (Figure 
A.1 C) and decay tau (Figure A.1 D) of AMPA as well as NMDA receptor-mediated components 
of mEPSCs between control and high glucose conditions in either WT or RAGE-KO group. There 
was, however, a significant main effect of high glucose treatment on the frequency of mEPSC 
(Figure A.2 A). Consistent with this, high glucose condition caused a significant increase in the 
frequency of mEPSC in both WT and RAGE-KO cultured hippocampal neurons (Figure A.2 A).    
 
A.3.2 High glucose increased RAGE expression and decreased AMPA GluA1 subunit 
expression in cultured hippocampal neurons from WT mice, while NMDA GluN1 subunit 
expression was affected in both WT and RAGE-KO neurons  
To evaluate if the observed changes in electrophysiological properties of cultured hippocampal 
neurons are correlated with changes in protein expression levels, western blotting was performed 
on whole cell extracts of hippocampal cultures maintained for 1-2 weeks in control and high 
glucose conditions in WT and RAGE-KO groups. We quantified expression of AMPA and NMDA 
receptor subunits as well as RAGE and RAGE-associated proteins (such as ADAM 10 and NF-
kB) to determine changes in glutamate receptors expression and potential involvement of RAGE 
in mediating these alterations.  
Immunoblotting analysis revealed both, an increase in RAGE and a decrease in GluA1 subunit of 
AMPA receptor in cultured hippocampal neurons exposed to high glucose condition in WT group 
(Figure A.3 A). High glucose, however, decreased the expression of GluN1 subunit of NMDA 
receptor in cultured hippocampal neurons from both WT and RAGE-KO mice (Figure A.3 C-D). 
We also observed an increased trend, although not significant, in both ADAM 10 and NF-kB 
expression in cultured hippocampal neurons exposed to high glucose condition (Figure A.3 A). 
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ADAM 10, however, did not show any increase in cultured neurons exposed to high glucose 
condition in the RAGE-KO group (Figure A.3 B). 
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Figure A.1. High glucose condition did not change the characteristics of NMDA and AMPA 
receptor-mediated components of mEPSCs. (A) Representative traces from WT and RAGE-KO 
cultured hippocampal neurons (P0-P2) exposed to 5 mM glucose (CNT) and 25mM glucose (HG) 
showing the average of mEPSCs collected from one pyramidal cell in the absence (brown trace) 
and in the presence (green trace) of AP-5. The brown trace (control) arises from the coactivation 
of AMPA and NMDA receptors. The green trace is representative of AMPA receptor-mediated 
component of mEPSCs when the NMDA receptor-mediated component was blocked by AP-5 (50 
μm). The blue trace shows the subtraction of the two traces, yielding the NMDA receptor 
component. Bar graphs summarize the mean (B) peak amplitude, (B) ionic charge and (C) decay 
tau of mEPSCs in the absence of AP-5 (control) and in the presence of AP-5 (AMPA) as well as 
in the subtracted trace (NMDA). Values are expressed as the mean ± SEM from WT CNT (n=10), 
WT HG (n=11), RAGE-KO CNT (n=9), and RAGE-KO HG (n=9). Means were statistically 
compared by two-way ANOVA, followed by Sidak’s multiple comparison test.  
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Figure A.2. High glucose condition caused a significant increase in the frequency of 
mEPSCs. Representative recordings of spontaneous mEPSCs from WT and RAGE-KO cultured 
hippocampal neurons (P0-P2) exposed to 5 mM glucose (CNT) and 25mM glucose (HG) before 
(A) and after (B) AP-5 (50 μm) treatment. Bar graphs summarize the mean frequency of mEPSCs 
in the absence (A) and in the presence (B) of AP-5. Values expressed as the mean ± SEM from 
WT CNT (n=10), WT HG (n=11), RAGE-KO CNT (n=9), and RAGE-KO HG (n=9); Means were 
statistically compared by two-way ANOVA, followed by Sidak’s multiple comparison test; * 
p<0.05. (T): Significant main effect of HG treatment (F(1, 35)=17.94, p<0.001 in A).  
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Figure A. 3. High glucose increased RAGE expression and decreased AMPA GluA1 subunit 
expression in cultured hippocampal neurons from WT mice, while NMDA GluN1 subunit 
expression was affected in both WT and RAGE-KO neurons. Representative immunoblots 
showing levels of AMPA receptor subunits and ADAM10, NF-kB and RAGE in whole-cell 
extracts of (A) WT and (B) RAGE-KO cultured hippocampal neurons as well as levels of NMDA 
receptor subunits in whole-cell extracts of (C) WT and (D) RAGE-KO cultured hippocampal 
neurons maintained in either 5 mM glucose (CNT) or 25 mM glucose (HG). Bar graphs show the 
mean ± SEM levels of each protein after normalization to tubulin expressed as a percentage of 
control (n=4 in each group). Means were statistically compared with the Mann-Whitney U test; * 
p<0.05. Protein samples for Western blotting were obtained from at least 3 independent sets of 
cultures, each culture was generated from the hippocampi of 5 neonatal (P0-P2) WT or RAGE-
KO mice.  
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A. 4 Discussion  
Glutamate receptors are shown to play important roles in controlling synaptic plasticity during 
learning and memory processes (Trudeau et al., 2004). Abnormal regulation of glutamate receptors 
thus appears to mediate impairments in synaptic plasticity and development of cognitive deficits 
in diabetes (Trudeau et al., 2004). In this regard, animal models of diabetes have shown 
electrophysiological and structural changes in AMPA and NMDA receptors (Valastro et al, 2002; 
Gardoni et al, 2002; Trudeau et al., 2004; Castilho et al., 2012; Viswaprakash et al., 2015; Nardin 
et al, 2016; Marshad et al., 2018; Wang et al., 2019).  
Our results show a decrease (although not significant) in the expression of GluA1 subunit of 
AMPA receptor in cultured hippocampal neurons exposed to high glucose condition in WT group. 
This is consistent with studies that showed reduced level of GluA1 subunit of AMPA receptor in 
the hippocampus of STZ-induced diabetic rats (Gagne et al., 1997; Viswaprakash et al., 2015), and 
inconsistent with a study that showed increased protein expression of GluA1 subunit of AMPA 
receptor in the hippocampus of STZ-treated rats (Wang et al., 2019).  
Our findings also show decreased expression of GluN1 subunit of NMDA receptor in both WT 
and RAGE-KO hippocampal cultures exposed to high glucose condition. Consistent with this, 
STZ-induced diabetic rats showed a significant reduction in hippocampal GluN1 subunit 
expression of NMDA receptor (Gardoni et al., 2002). On the contrary, increased expression of 
GluN1 subunit of NMDA receptor has been reported in a recent study in the hippocampus of STZ-
induced diabetic rats (Wang et al., 2019).  
Our data, on the other hand, did not show any changes in the electrophysiological properties of 
AMPA and NMDA-receptor mediated components of mEPSCs in cultured hippocampal neurons 
exposed to high glucose condition. There was, however, a significant increase in the frequency of 
mEPSCs in both WT and RAGE-KO cultured hippocampal neurons exposed to high glucose 
condition. Consistent with this, higher frequency of mEPSCs, indicative of increased probability 
of presynaptic neurotransmitter release (Ju et al., 2016), has been reported in dorsal motor nucleus 
of the vagus nerve (DMV) of hyperglycemic mice as compared to control, while no significant 
difference was found between the two groups in the amplitude of mEPSCs (Bach et al., 2015). 
Similarly, increased frequency of mEPSCs has been shown in kidney-related paraventricular 
nucleus (PVN) neurons of the hypothalamus in STZ-induced diabetic mice as compared with 
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controls, with no significant impact on the amplitude of mEPSCs (Jiang et al., 2013). However, 
AMPA receptor-mediated mEPSCs showed reduced amplitude and frequency in CA1 pyramidal 
neurons of the hippocampus in STZ-induced diabetic rats (Viswaprakash et al., 2015).  
Overall, some previous findings are consistent with the data presented in the current chapter, but 
research on the effect of diabetes on glutamate receptors and how this affects synaptic plasticity is 
still ongoing and reports are controversial. The discrepancy between cultured neurons and actual 
hippocampal tissue might be a result of culture conditions, which points to the limitations of using 
cultured neurons to study brain-affecting diseases and highlights the need to validate results in 
actual tissues. However, since our findings of decreased GluN1 subunit expression of NMDA 
receptor, and increased frequency of mEPSCs were observed in neurons exposed to high glucose 
condition from both WT and RAGE-KO genotypes, we can infer that these effects could be 
independent of RAGE expression and/or signaling. On the other hand, decrease in GluA1 subunit 
expression of AMPA receptor, accompanied by significant increase in RAGE expression, in 
cultured hippocampal neurons exposed to high glucose condition in the WT group can suggest the 
role of RAGE in mediating this effect. However, further investigations are required to validate 
these results in animal models of diabetes.  
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